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COMBINATION THERAPY WITH AEROSOL IL-2 AND NK CELLS 
FOR THE TREATMENT OF OSTEOSARCOMA LUNG 
METASTASIS 
 
Sergei R. Guma De la Vega, BS 
 
Supervisory Professor: Eugenie S. Kleinerman, MD 
 
 
The survival of patients with osteosarcoma lung metastases has not improved in 
the last 20 years. Novel alternative therapies are needed. The purpose of this 
investigation was to evaluate the efficacy of combining natural killer [NK] cell therapy 
with aerosol interleukin-2 [IL-2] for the treatment of osteosarcoma lung metastasis. The 
expression of NKG2D ligands was analyzed in five different human osteosarcoma cell 
lines and 103 patient samples (47 from primary tumors and 56 from lung metastases). 
We discovered that osteosarcoma expresses the ligands for the NKG2D. In vitro studies 
demonstrated that NK-mediated killing of osteosarcoma cells is dependent on the 
NKG2D-NKG2D ligand interaction and that cytotoxicity correlates with the level of 
NKG2D ligand expression. Aerosol IL-2 increased NK cell numbers in the lung but not in 
other organs. This increase in NK numbers was due to an aerosol IL-2-induced increase 
in NK proliferation that occurs almost exclusively in the lung. Aerosol IL-2 also 
increased the NK cell infiltration within the lung metastatic nodules. Compared to 
control, NK cell treatment alone and aerosol IL-2 treatment alone, aerosol IL-2 + NK cell 
therapy had a higher therapeutic efficacy, as judged by a greater decrease in the 
number and sizes of tumors nodules, as well as by a greater increase in tumor 
apoptosis. Furthermore, aerosol IL-2 + NK cell therapy significantly improved the 
vii

survival of mice with osteosarcoma lung metastasis. In addition, there was no evidence 
of IL-2-associated systemic toxicities.  
In conclusion, combining NK cell therapy with aerosol IL-2 achieved organ-
specific NK cell migration and proliferation in the lung and reduced pulmonary 
metastatic burden, while at the same time avoided the systemic toxicities associated 
with IL-2.  We believe that a combination therapy consisting of aerosol IL-2 with NK cell 
infusions can be a new and effective therapeutic approach for the treatment of patients 
with osteosarcoma lung metastasis.  
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Introduction: background, rationale and research plan 
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Osteosarcoma 
 Osteosarcoma is the most common primary bone cancer in pediatric 
patients. It is the second most common primary malignant bone tumor in the 
general population, after multiple myeloma. 75% of all osteosarcoma cases occur 
between the ages of 15 and 25 years [1]. It is the fifth most common primary 
malignant tumor in adolescence. The most common presenting symptom is pain 
at the extremities, usually accompanied by a palpable mass upon physical 
examination [2].  
 The treatment of osteosarcoma originally consisted of surgery with or 
without radiation therapy. Overall 2-year survival rates were 15 – 20%. In most 
cases, microscopic metastases are present in the lung at the time of diagnosis. 
For this reason, osteosarcoma that was only treated with surgery and/or radiation 
had a metastatic recurrence of 80% [3]. With the advent of neoadjuvant and 
postoperative chemotherapy for primary osteosarcoma treatment, 5 year survival 
rates have increased to 68% [4]. The current standard of care consists of surgery 
and a combination of high-dose methotrexate, cisplatin, adriamycin and 
ifosfamide [2]. However, prognosis for patients with pulmonary metastasis is 
dismal, with a 5 year survival of 33% [5].  
 The most frequent site of osteosarcoma metastasis is the lung (81.2%), 
followed by the bone (34.2%) [5]. Most deaths are due to respiratory failure 
caused by metastatic burden [2]. The current standard treatment for 
osteosarcoma lung metastasis consists of surgical resection with preoperative 
and postoperative chemotherapy.  Chemotherapy consists of cisplatin, 
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doxorubicin, and high-dose methotrexate with leucovorin. The survival for 
relapsed patients is very low, with less than 20 % long term post-relapse survival. 
Treatment for recurrent lung metastasis is complete surgical removal of all 
metastatic foci. The role of chemotherapy for recurrent osteosarcoma is much 
less defined, with no accepted standard therapy [6]. It is imperative to discover 
and develop new alternative therapies for primary and recurrent osteosarcoma 
lung metastasis.  
 
Immunotherapy for osteosarcoma  
 
 Our laboratory has had success with the use of immunotherapy for the 
treatment of osteosarcoma in pre-clinical and clinical settings. We demonstrated 
that liposomal muramyl tripeptide [L-MTP-PE] activates the tumoricidal properties 
of blood monocytes [7]. A Phase II trial demonstrated that L-MTP-PE significantly 
increased the progression-free interval and the long-term survival of patients with 
relapsed pulmonary osteosarcoma metastasis [8]. A Phase III trial demonstrated 
that the addition of L-MTP-PE to standard chemotherapy increased the 6-year 
survival of pediatric patients with primary osteosarcoma from 70 to 78% [9]. L-
MTP-PE has been approved for the treatment of high-grade resectable 
nonmetastatic osteosarcoma in the European Union. It has been the first new 
agent approved for the treatment of osteosarcoma in the last 20 years [10].  
 We have also demonstrated the effectiveness of using genetically 
modified T cells against osteosarcoma lung metastasis in a preclinical model. We 
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found that IL-11RĮ is highly expressed in patient specimens of osteosarcoma 
lung metastasis. T cells were genetically modified to express a chimeric antigen 
receptor against IL-11RĮ. Treatment with IL-11RĮ-CAR-specific T cells 
significantly reduced pulmonary osteosarcoma metastasis in an athymic mouse 
model. [11]. The success of these immunotherapies supports the investigation of 
other immune-based therapies, such as adoptive natural killer [NK] cell therapy.  
 
Natural killer cells 
 
 Human NK cells comprise about 10 – 15% of peripheral lymphocytes [12].  
They are considered part of the innate immune system due to their ability to 
detect and kill virus infected and tumor cells without prior sensitization [13]. They 
play an essential role in immunosurveillance. Patients with lower peripheral 
natural cytotoxicity have greater cancer predisposition [14]. Patients with NK cell 
deficiencies are more susceptible to viral infection, especially from members of 
the Herpesviridae family [15]. In addition to their cytotoxicity, activated NK cells 
also secrete a variety of cytokines, including INFܵ, TNFĮ, IL-12, GM-CSF and 
MIP-1Įȕ, which can activate other members of the immune system [16]. They 
themselves can be stimulated by IL-12, IL-15, IL-18, IL-21 and IL-2 [17]. 
 The recognition of a target cell by NK cells is a complex interplay between 
inhibitory and activating NK receptors and their respective ligands. CD94/NKG2A 
heterodimers and the killer-cell immunoglobulin-like receptors (KIRs) are the 
major inhibitory receptors in human NK cells. KIRs play a major role in NK cell 
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self-tolerance [18]. They recognize specific HLA-B and HLA-C allotypes, while 
CD94/NKG2A heterodimers bind to HLA-E [19]. Loss of HLA is a frequent 
adaptive mechanism used by cancer cells to escape cytotoxic T cell recognition. 
However, this same mechanism renders them more susceptible to NK 
cytotoxicity [20]. In humans, the major activating NK receptors are NKG2D, D-
NAM1, and the natural cytotoxicity receptors (NCRs) [21]. The NCRs, which 
consist of NKp46, NKp44 and NKp30, recognize transmembrane-anchored 
polypeptides with immune tyrosine-based activating motifs (ITAM). The specific 
ligands for the NCRs are currently unknown, but current data suggest that normal 
tissues either do not express these ligands or that they express very low levels of 
them [22]. D-NAM1 recognizes poliovirus receptor and nectin-2, both members of 
the nectin family. D-NAM1 ligands are expressed in a variety of human cancers. 
However they are also ubiquitous on normal tissue. This suggests that NK 
activation by D-NAM1 is highly dependent on the HLA status [22]. NKG2D is the 
best characterized NK activating receptor. It binds and recognizes MIC A/B and 
the ULBP family members. NKG2D ligands are generally absent from normal 
cells. MIC A/B is only expressed on GI epithelial cells on healthy individuals. This 
is believed to be due to epithelial contact with intestinal microbes. NKG2D 
ligands are upregulated under conditions of cellular stress, including viral 
infection, classical heat shock and malignant transformation [23]. Therefore, 
NKG2D ligands tend to be expressed on a variety of human cancers [24-27]. 
Activation signals generated by NKG2D-ligand binding can bypass signals 
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generated by NK inhibitory receptors [23], rendering NK-mediated killing of 
cancer cells possible even in the presence of HLA expression.  
  NKG2D recognition of its ligand activates NK killing through the secretion 
of cytotoxic granules into the intercellular space. Major granule proteins include 
perforin, which disrupts the cellular membrane, and the granzymes, serine 
proteases that trigger the apoptotic pathway. NK cells also express TRAIL and 
FasL, both of which can trigger apoptosis by binding to their corresponding 
receptors [28]. In addition to NK killing, target recognition also triggers NK 
cytokine production [29]. This further contributes to the overall immune response. 
For example, activated NK cells secrete INFܵ and MIP-1Į, potent macrophage 
activators [17].  
 
NK cell cancer immunotherapy 
 
  In 2002, Ruggeri et al [30] demonstrated that the survival of AML patients 
treated with T cell-depleted allogeneic hematopoietic transplantation was 
significantly increased in the presence of KIR ligand incompatibility form donor to 
recipient. KIR ligand incompatibility increased 5 year survival from 5% to 60%. It 
also prevented the appearance of graft-versus-host disease. Increased 5 year 
survival (from 48% to 87%) was subsequently observed in CML and MDS 
patients treated with T cell depleted allogeneic transplantation in the presence of 
KIR mismatch [31]. This drastic increase in survival and the leading role NK cells 
played in the eradication of said malignancies has increased interest in the use of 
7

NK cells as potential new anti-cancer therapeutics. NK cell associated graft-vs-
tumor effects have also been reported in patients with pediatric solid tumors 
treated with haploidentical stem cell transplantation [32, 33].  
 A number of phase I clinical trials have been performed to evaluate the 
safety of allogeneic natural killer cell transplantation as treatment for AML. These 
have demonstrated successful engraftment of the donor NK cells, with little to no 
side-effects and with evidence of clinical response [34-36].  However, these trials 
required the administration of intravenous IL-2 to maintain in vivo NK expansion.  
 One of the limiting factors of NK cell therapy is the ability to grow them in 
sufficient numbers. The highest dose of NK cells that have been infused into 
patients was generated through ex vivo expansion [37]. Several different 
methods have been developed for ex vivo NK cell expansion. The uses of both 
soluble and membrane-bound IL-15, as well as other cytokines, such as IL-2 and 
IL-7, have been studied [38]. Denman et al established an ex vivo method to 
expand donor NK cells using IL-2 and a genetically modified K562 artificial 
antigen presenting cell [aAPC] expressing membrane bound IL-21[39]. This 
method promoted a sustained mean 47,967-fold NK expansion after 42 days, as 
well as increasing NK cytotoxicity and NKG2D expression. In addition, 
membrane bound IL-21 promoted a significant increase in NK telomere length 
and greatly reduced senescence.  In contrast, other expansion methods, such as 
those using membrane bound IL-15, reduced telomere length, inducing NK 
senescence by three weeks.  
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We believe osteosarcoma can provide an ideal target for NK cell 
immunotherapy. In vitro studies have demonstrated high NK cytotoxicity against 
pediatric solid tumor cell lines [40]. Among those susceptible to NK killing are 
Ewing’s Sarcoma and osteosarcoma [40-42]. Studies have also report elevated 
expression of specific NK activating ligands in osteosarcoma [42]. Additionally, 
NK activity and NK absolute counts correlated positively with clinical outcome in 
osteosarcoma patients treated with interleukin-2 [43]. Recent studies have also 
reported the feasibility and safety of using NK cell therapy against solid tumors in 
the lung [44]. Thirty minutes after transfusion, the lung serves as a reservoir for 
allogeneic NK cells, before they redistribute to the rest of the body [45]. This 
makes the lung an ideal organ for NK therapy.  
 
Aerosol Interleukin-2  
As mentioned before, most clinical trials using NK adoptive therapy use 
concomitant interleukin-2 (IL-2) to maintain NK activation in vivo [34-36]. Even 
trials using ex vivo NK expansion require IL-2. The highest doses of NK cells to 
be infused into patients were generated through ex vivo NK expansion using IL-
2, OKT3 and PBMC feeder cells. Patients received an average of 4.7 X 1010 NK 
cells and these cells were persistent in the peripheral circulation. However, tumor 
regression was not observed, and the persistent NK cells showed significantly 
lower levels of NKG2D expression and could not lyse tumor cells in vitro unless 
reactivated with IL-2 [37]. This result suggests that even with high NK numbers, 
systemic IL-2 is required for NK cytotoxicity in vivo. 
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IL-2 is a cytokine that augments the growth and cytotoxicity of T and NK 
cells, as well as driving T cell differentiation and increasing B cells’ antibody 
production [46]. It is a FDA-approved therapeutic for metastatic melanoma [47] 
and renal cell carcinoma [48]. However, high dose IL-2 therapy is complicated by 
serious, sometimes life threatening side effects, including oliguria, hypotension, 
elevated bilirubin and creatinine levels, thrombocytopenia, and capillary-leak 
syndrome, which can lead to fluid retention, adult respiratory distress syndrome 
and myocardial infarction [49].  
We propose to use aerosol IL-2 in order to increase the number of injected 
NK cells numbers in the lung, while at the same time avoiding the systemic 
toxicities associated with IL-2. The safety of aerosol IL-2 has been established by 
several clinical trials. Aerosol IL-2 produces only low to mild toxicities [50]. Cough 
is the most common side-effect [51]. Patients treated with aerosol IL-2 report a 
better quality of life than those treated with systemic IL-2 [52]. Furthermore, an 
increased survival has been reported for patients with lung metastasis from renal 
cell carcinoma treated with aerosol IL-2 [50, 53, 54]. Aerosol IL-2 recruits 
activated lymphocytes to the lung periphery in a dose-dependent manner, as 
measured by broncho-alveloar lavage [BAL] [55]. Aerosol IL-2 therapy in dogs 
has also shown very minimal toxicity. As in humans, BAL revealed an increase in 
activated lymphocytes [56].  
Normally, transfused allogeneic NK cells aggregate in the lung for the first 
thirty minutes. This is followed by rapid redistribution to the whole body, with a 
predilection for the liver, spleen and bone marrow [45]. We believe that giving 
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aerosol IL-2 concomitantly with NK cells will cause the NK cells to be retained 
and expanded in the lung.  
Aim of Study 
 Our central hypothesis is that aerosol IL-2 will augment the efficiency of 
NK cell therapy against osteosarcoma lung metastasis by increasing their 
numbers in the lung, enabling greater contact and interaction with their target 
cells. We first determined osteosarcoma’s expression of NKG2D ligands as well 
as its susceptibility to NK cytotoxicity. Using Nu/Nu mice we also determined if 
aerosol IL-2 increases the number of injected NK cells in the lung. We proceeded 
to determine if aerosol IL-2 increases the efficiency of NK cell therapy in mice 
with osteosarcoma lung metastasis.  
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RESULTS 
 
 
 
 
 
 
 
 
Chapter 2 
NK cells kill osteosarcoma cells in a NKG2D dependent manner 
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RATIONALE 
 The recognition of target cells by NK cells is a complex interplay between 
inhibitory and activating NK receptors and their respective ligands. The killer-cell 
immunoglobulin-like receptors [KIRs] are the major inhibitory receptors on human 
NK cells. They recognize specific HLA-B and HLA-C allotypes [57]. NKG2D is a 
major NK activating receptor, specifically associated with tumor surveillance [58]. 
NKG2D recognizes MIC A/B [59] and the ULBP proteins [60], which are 
overexpressed on several cancers [25, 27, 61]. NK-based immunotherapy is 
dependent on tumor NKG2D ligand status [58, 62, 63]. In order to determine if 
NK cell therapy could be an effective tool against osteosarcoma, we determined 
the NKG2D ligand expression on five different osteosarcoma cell lines. HLA-
A,B,C expression was also evaluated. NK cytotoxicity against these cell lines 
was determined and correlated with NKG2D ligand expression. In addition, to 
further examine the dependence of NK cytotoxicity on NKG2D ligand expression, 
the NKG2D –NKG2D ligand interaction was blocked, with monoclonal antibodies.  
RESULTS 
Human osteosarcoma cell lines express NKG2D ligands 
 NKG2D ligands are highly expressed among LM7, CCHOSD, U2OS and 
TE-85 osteosarcoma cells (Figure 1). With the exception of KRIB, all cell lines 
expressed a high percentage (from 85 to 99%) of HLA-A, B, C and ULBP2. In 
addition, MIC A/B was expressed on LM7, U2OS and TE-85, while ULBP1 was 
expressed in CCH-OS-D. LM7[64], U2OS [65], CCH-OS-D [66] and TE-85 [65] 
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are non-transformed cell lines derived from patient samples, while KRIB was 
derived from HOS transfected with v-K-ras [65]. This may explain the difference 
between KRIB cells and the 4 other cell lines.  
 
  
 
Human NK cells are cytotoxic against human osteosarcoma cells 
  We determined NK cytotoxicity against LM7, CCH-OS-D, KRIB, TE-85 
and U2OS. Since NK-mediated cytotoxicity is species specific, K7M3 mouse 
osteosarcoma cells were used as the negative control. NK cells were cytotoxic to 
Figure 1: NKG2D Ligand Expression. Human osteosarcoma cell lines were analyzed 
for the expression of NKG2D ligands and HLA-ABC using flow cytometry. LM7, 
U2OS, TE-85 and CCHOSD cells expressed high levels of NKG2D ligands. Figure 
and figure legend were originally published in Pediatric Blood and Cancer 2013. 
This material is reproduced with permission of John Wiley & Sons, Inc.. 
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all five human cell lines. KRIB cells were the least sensitive to NK-mediated 
killing (Figure 2). At 1:1 effector: target [E:T] ratio NK cell-mediated cytotoxicity 
against LM7, CCH-OS-D, U2OS and TE-85 cells was 45% compared to 10% 
cytotoxicity against KRIB cells.  The low level of NKG2D ligands on KRIB cells 
correlates with the lower cytotoxicity value.  
 
 
 
NK cytotoxicity against osteosarcoma is dependent on NKG2D-NKG2D 
ligand interaction 
 NK cytotoxicity is dependent on the interaction between the NKG2D 
receptor on NK cells and its corresponding ligand on the tumor cell. Blocking the 
NKG2D receptor significantly reduced NK cytotoxicity against LM7 cells (Figure 
Figure 2: NK-cell mediated cytotoxicity. NK-cell mediated cytotoxicity against KRIB, 
LM7, TE-85, U20S and CCH-OS-D osteosarcoma cells was quantified using [
3
H]-thymidine 
cytotoxicity assay. K7M3 mouse osteosarcoma cells served as the negative control. Figure 
and figure legend were originally published in Pediatric Blood and Cancer 2013. This 
material is reproduced with permission of John Wiley & Sons, Inc.. 
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3A). At 1:5 E:T ratio, 10 µg/ml of anti-NKG2D antibody decreased NK-mediated 
cytotoxicity from 70% ± 15  to 22.6% ± 10.8 (P= 0.02). At 1:10 E:T ratio 
cytotoxicity decreased from 73% + 6.2 to 12 % + 12.7 (P= 0.02). Similarly 
blocking the ligand also decreased NK-mediated killing (Figure 3B). ULBP2 was 
selected since this ligand is expressed on all the non-transformed cell lines. 
Blocking ULPB2 in LM7 significantly reduced NK mediated killing. At 1:5 E:T 
ratio, 10 µg/ml of anti-ULBP2 antibody decreased cytotoxicity from 70% ± 15  to 
29.8%  ± 10  (P = 0.004). At a 1:10 E:T ratio, cytotoxicity decreased from 73% + 
6.2 to 39% + 9.4 (P= 0.01). 
 
 
  
 
A LM7 
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SUMMARY 
 These data support the concept of using NK immunotherapy against 
osteosarcoma. I have demonstrated that human osteosarcoma cell lines express 
NKG2D ligands. Accordingly, human NK cells are cytotoxic against these cell 
lines. The exception was the KRIB cell line, which had very low levels of NKG2D 
ligand expression. The fact that the KRIB cell line was derived from HOS with a 
v-K-ras transfection, while the others are non-transformed cell lines derived from 
patient samples, may explain KRIB’s low NKG2D ligand expression and, 
B LM7 
Figure 3:  Blocking NKG2D- NKG2D ligand interaction hinders NK cytotoxicity against 
osteosarcoma A. NK cells were incubated with anti-hNKG2D prior to the addition to LM7 
cells. B. LM7 cells were incubated with anti-hULBP2 prior to addition of NK cell. P<0.05 was 
considered significant. 
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consequently, lower NK sensitivity. I further demonstrated that by blocking the 
NKG2D-NKG2D ligand interaction, NK cytotoxicity was hindered. These results 
support our hypothesis that NK cytotoxicity against osteosarcoma correlates and 
is dependent on NKG2D ligand expression. In potential future clinical trials, the 
effectiveness of NK cell therapy against osteosarcoma may be predicted by the 
levels of NKG2D ligand expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18

RESULTS 
 
 
 
 
 
 
 
 
Chapter 3 
The expression of NKG2D ligands in osteosarcoma patient samples. 
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RATIONALE 
 After demonstrating that human osteosarcoma cell lines have an 
increased NKG2D ligand expression as well as a high sensitivity to NK killing, we 
further investigated the plausibility of NK cell therapy by determining the 
expression of NKG2D ligands in patient osteosarcoma samples. Previous 
investigations [58, 62, 63] have demonstrated that the status of NKG2D ligand 
expression is important for immune surveillance and for effective cytokine 
therapies. We have confirmed that NK cytotoxicity against osteosarcoma 
correlates with and is dependent on NKG2D-NKG2D ligand interaction.  
Therefore, we can predict the effectiveness of NK cell based immunotherapy by 
determining the level of osteosarcoma NKG2D ligand expression.  
Paraffin-embedded microarray slides of patient osteosarcoma tissues from 
the University of Michigan were kindly provided by Dr. Dennis Hughes, MD/PhD 
(Division of Pediatrics, The University of Texas MD Anderson Cancer Center).  
The tissue microarray slides contained 47 primary osteosarcoma and 56 
osteosarcoma lung metastasis samples. We determined NKG2D ligand 
expression through immunohistochemistry using a recombinant human 
NKG2D/Fc Chimera.  
RESULT  
NKG2D ligands were expressed in 27(57%) of the 47 primary tumor 
specimens. Staining was weak in 18 specimens (38%), moderate in 6 specimens 
(12.8%) and strong in 3 specimens (6.4%) (Figure 4A). NKG2D ligands were 
expressed in 44 (77%) of the 56 lung metastasis specimens. Staining was weak 
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in 22 specimens (39%), moderate in 18 specimens (32%) and strong in 4 
specimens (7.5%) (Figure 4B). (Originally published in Pediatric Blood and 
Cancer 2013. This material is reproduced with permission of John Wiley & Sons, 
Inc.) 



Figure 4: Expression of NKG2D ligands on human osteosarcoma tumors. 
Human osteosarcoma patient samples from primary tumor (A) and lung 
metastasis (B) were analyzed for the expression of NKG2D ligands by 
immunohistochemistry using a rhNKG2D/Fc. Positive NKG2D ligand staining 
was classified as negative, weak, moderate or strong. Figure and figure 
legend were originally published as supplemental material in Pediatric Blood 
and Cancer 2013). This material is reproduced with permission of John Wiley 
& Sons, Inc.. 
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SUMMARY  
 The data also demonstrate that a high percentage of osteosarcoma 
express NKG2D ligands. It also demonstrates that osteosarcoma pulmonary 
metastasis has a higher NKG2D ligand expression than primary tumors. This 
results validate that osteosarcoma lung metastasis could be an ideal target for 
NK cell therapy.  
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Chapter 4 
Aerosol IL-2 increases the number and proliferation of NK cells in the lung 
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RATIONALE 
 In the previous chapters, we have shown that osteosarcoma cells are 
sensitive to NK cell killing and that both osteosarcoma cell lines and patient 
tissue samples expresses the ligands required for this sensitivity. However, for 
NK cell therapy to be effective, a sufficient number of NK cells must come into 
contact with their target cells. Since we are specifically interested in pulmonary 
osteosarcoma metastasis, we proposed using aerosol IL-2 to increase the 
number of injected NK cells present in the lung.  
 IL-2 is a cytokine that stimulates the growth, cytotoxicity and survival of 
NK cells [67]. For this reason, it has been given as an in vivo activator in clinical 
studies involving NK cell therapy [68, 69]. Yet, high dose IL-2 induces a myriad of 
life-threatening side effects, including oliguria, hypotension, and elevated bilirubin 
and creatinine levels [68]. Furthermore, its effects are not organ specific. We 
proposed using aerosol IL-2 to stimulate the injected NK cells in the lung 
specifically, the most frequent site for osteosarcoma metastasis [70].  
 Nu/Nu mice were injected with human NK cells and treated with either 
aerosol IL-2 or aerosol PBS. The effect of aerosol IL-2 on NK cell numbers in the 
lung, liver, spleen, heart and kidney was determined. To further corroborate 
these findings, we determined the percentages of proliferating NK cells in the 
lungs, spleen, liver and bone marrow.  
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RESULTS 
Aerosol IL-2 increased NK cells in the lungs  
Aerosol IL-2 increased the number of NK cells in the lung 3 days after 
human NK cell injection (P = 0.02; Figure 5). There was a slight increase 1 day 
after injection when compared to control yet not in a statistically significant 
manner (P = 0.26). The number of NK cells in the lung for aerosol PBS treated 
mice did not change between 1 day, 3 days and 1 week after NK cell injection. 
After one week, the number of NK cells in the lung of aerosol IL-2 treated mice 
decreased to levels similar to aerosol PBS-treated mice, suggesting aerosol IL-
2’s effect on the injected NK cells’ pulmonary presence is time-dependent.  
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Figure 5. Aerosol IL-2 increases human NK cells in the lungs. Nude mice were 
injected with 5x10
7
 CM-DiI-labeled human NK cells per mouse. Aerosol PBS or IL-2 was 
given 1 day prior to and on the day of NK cell infusion and then continued every other day 
for 1 week. Fluorescent microscopy was used to detect the presence of CM-Dil+ cells 
(red) in lungs at 1, 3 and 7 days after NK cell infusion. Cellular nuclei were identified with 
Hoechst33258 (blue). Mean positive fluorescence was quantified using the Simple PCI 
software in 5 random fields per section. Representative pictures of NK cell presence in the 
lung at the different time points are shown. Figure and figure legend were originally 
published in Pediatric Blood and Cancer 2013. This material is reproduced with 
permission of John Wiley & Sons, Inc..
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Aerosol IL-2 did not increase NK cells in the spleen, liver, heart or kidney 
 High numbers of injected NK cells were observed in the spleen and liver 
(Figure 6 A,B), suggesting that a large portion of infused NK cells localize into 
these two organs. However, there was no aerosol IL-2-associated increase. It is 
worthwhile to note that there is a non-statistically significant decreasing trend in 
the number of NK cells present in these organs when aerosol IL-2 was given. 
This is consistent with the increased presence of NK cells seen in the lung. There 
was a very minimal presence of injected NK cells in the heart and kidney (Figure 
6 C,D) with no increase associated with aerosol IL-2 treatment. 
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Aerosol IL-2 
Spleen Liver Heart Kidney
Aerosol PBS 
Figure 6. Aerosol IL-2 does not increase human NK cells in the spleen, liver, heart or 
kidney. Mean positive fluorescence was quantified for the presence of CM-DiI+ NK cells in 
A spleen, B liver, C heart and D kidney. E. Representative sections from organs 3 days 
after NK cell infusion. Figure and figure legend were originally published in Pediatric Blood 
and Cancer 2013. This material is reproduced with permission of John Wiley & Sons, Inc.. 
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Aerosol IL-2 increased the proliferation of NK cells in the lung 
 We proceeded to determine if the increase in lung NK cells caused by 
aerosol IL-2 was due to an increase in NK cell proliferation. For example, the 
increase of mouse NK cells observed in the lung after intranasal respiratory viral 
infection is not due to an increase of NK cell proliferation in the lung. Instead it is 
caused by an increase in proliferation of the NK cells in the bone marrow [71]. To 
determine if that is the case for aerosol IL-2 therapy, we injected Nu/Nu mice with 
human NK cells and treated them with either aerosol PBS or aerosol IL-2. We 
injected these mice with BrdU 3 hours prior to euthanasia and harvested cells 
from their lungs, spleen, liver and bone marrow. Cells that stained positive for 
human NKp46 and BrdU were identified as proliferating NK cells; cells that were 
NKp46+/BdU- were identified as non-proliferating NK cells.  
 Aerosol IL-2 increased human NK proliferation in the lung. This was seen 
by a marked increase in the percentage of proliferating NK cells seen 24 and 72 
hours after NK injection (Figure 7). 24 hours after injection, 20% ± 4 of the 
human NK cells in the lung of mice treated with aerosol IL-2 were proliferating, 
compared to 8% ± 0.15 of those in the lung of aerosol PBS treated mice (P = 
0.03). The difference between treatments increased over time. 72 hours after 
injection, 76% ± 9.5 of the human NK cells in the lung of mice treated with 
aerosol IL-2 were proliferating, compared to 9.2% ± 6.2 of those in the lung of 
mice treated with aerosol PBS (P = 0.007).  
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Aerosol IL-2 increased the proliferation of NK cells in the bone marrow 
 A large percentage of human NK cells were proliferating in the bone 
marrow, in both aerosol IL-2 and aerosol PBS treated mice (Figure 8). However, 
there was an increase in the percentage of proliferating NK cells found in the 
bone marrow of mice treated with aerosol IL-2. 24 hours after injection, 93.6 % ± 
4.8 of the human NK cells in the bone marrow of mice treated with aerosol IL-2 
Figure 7: Aerosol IL-2 increases the percentage of proliferating NK cells in the lung. 
Nude mice were injected with 5x10
7
 human NK cells per mouse. Aerosol PBS or IL-2 was 
given 1 day prior to and on the day of NK cell infusion and then continued every other day. 
BrdU reagent was injected intraperitoneally 3 hours prior to euthanasia. Lungs were 
harvested and minced. Single-cell suspensions were prepared by passage through cell 
strainers. Flow cytometry was used to identify NK cells with anti-human NKp46 staining and 
proliferating cells with anti-BrdU staining. P< 0.5 was considered significant.  
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were proliferating, compared to 65.5% ± 0.15 of those in the bone marrow of 
aerosol PBS treated mice (P = 0.03). 72 hours after injection, the percentage of 
proliferating NK cells in the bone marrow decreased. 58.5 % + 1.5 of the human 
NK cells in the bone marrow of mice treated with aerosol IL-2 were proliferating, 
compared to 23.8% ± 8.9 of those in the bone marrow of mice treated with 
aerosol PBS. At 72 hours after injection, the difference between the percentage 
of proliferating NK cells between the two treatment groups was not statistically 
significant (P = 0.058).  
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Aerosol IL-2 did not increase the proliferation of NK cells in the spleen or 
liver 
 In both the aerosol IL-2 and aerosol PBS treated-mice, a very low 
percentage of NK cells were proliferating in the spleen and liver 24 hours after 
NK cell injection (Figure 9). In the spleen, 2.55 % ± 2.55 of the human NK cells of 
mice treated with aerosol IL-2 were proliferating,  compared to 2.3% ± 2.23 of 
Figure 8: Aerosol IL-2 increases the percentage of proliferating NK cells in the bone 
marrow. Nude mice were injected with 5x10
7
 human NK cells per mouse. Aerosol PBS or IL-
2 was given 1 day prior to and on the day of NK cell infusion and then continued every other 
day. BrdU reagent was injected intraperitoneally 3 hours prior to euthanasia. Bone marrow 
cells were obtained by flushing femurs and iliac crest with PBS. Flow cytometry was used to 
identify NK cells with anti-human NKp46 staining and proliferating cells with anti-BrdU 
staining. P < 0.05 was considered significant. 
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human NK cells in mice treated with aerosol PBS (P = 0.9). In the liver, 5.1 % ± 
1.1 of the human NK cells of mice treated with aerosol IL-2 were proliferating,  
compared to 4.2% ± 1.6 of human NK cells in mice treated with aerosol PBS (P = 
0.72). The difference between the percentages of proliferating NK cells between 
the two treatment groups was not statistically significant. At 72 hours, the 
percentages of proliferating NK cells increased in the two organs, yet the 
differences between the two groups remained statistically insignificant.  In the 
spleen, 44.1 % ± 8.4 of the human NK cells of mice treated with aerosol IL-2 
were proliferating,  compared to 23.3% ± 9.1 of human NK cells in mice treated 
with aerosol PBS (P = 0.1). In the liver, 11.7 % ± 3.8 of the human NK cells of 
mice treated with aerosol IL-2 were proliferating,  compared to 16.3% ± 10.7 of of 
the human NK cells of mice treated with aerosol PBS (P = 0.74). 
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Figure 9: Aerosol IL-2 does not increase the percentage of proliferating NK cells in 
the spleen or spleen. Nude mice were injected with 5x10
7
 human NK cells per mouse. 
Aerosol PBS or IL-2 was given 1 day prior to and on the day of NK cell infusion and then 
continued every other day. BrdU reagent was injected intraperitoneally 3 hours prior to 
euthanasia. Spleens and livers were harvested and minced. Single-cell suspensions 
were prepared by passage through cell strainers. Flow cytometry was used to identify 
NK cells with anti-human NKp46 staining and proliferating cells with anti-BrdU staining. P 
< 0.05 was considered significant.  
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SUMMARY 
 We have demonstrated that aerosol IL-2 treatment increases the number 
of injected NK cells in the lung. In contrast, it does not increase the number of NK 
cells in the spleen, liver, heart or kidney. This result suggests that the effect of 
aerosol IL-2 on NK cells is organ specific. We further demonstrated that a higher 
percentage of NK cells in the lung are proliferating when aerosol IL-2 is given. 
This suggests that aerosol IL-2 is directly stimulating the proliferation of NK cells 
in the lung. This effect is seen 24 hours after NK cell injection, and continues to 
increase at least up to 72 hours after NK cell injection.  
 Aerosol IL-2 did not increase the proliferation of NK cells in the liver or 
spleen. Aerosol IL-2 slightly increased the proliferation of human NK cells in the 
bone marrow.  
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Chapter 5 
Aerosol IL-2 increased the efficacy of NK cells against metastatic 
osteosarcoma in vivo 
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RATIONALE 
 Our results have indicated that human NK cells are cytotoxic against 
human osteosarcoma cells in vitro. Our results have also indicated that aerosol 
IL-2 increases the number of injected NK cells in the lung. We hypothesized that 
in the presence of pulmonary osteosarcoma metastasis, aerosol IL-2 would 
increase the number of NK cells that come in contact with their target tumor cells, 
enhancing killing. In this chapter, I describe how we tested this hypothesis.   


 We used our established osteosarcoma pulmonary metastasis model [64].
3 million LM7 cells/mouse were injected intravenously through the tail vein of 
nu/nu mice. The presence of micrometastasis was confirmed through H&E at 5 
weeks in a group of 3 mice. Treatment was then initiated with aerosol PBS, 
Day0 
LM7I.V.
Injection 
Week5 
Micro 
Metastasis
Week6 
Treatment
d
Week11 
Endof
Treatment 
5Weeks 
Figure 10. Schematic diagram of in vivo model experimental design. Nude mice 
were injected i.v. with 3 x 10
6
 LM7 cells. Presence of micrometastasis was confirmed by 
H&E at week 5. Therapy was initiated on week 6. Mice were treated with aerosol PBS, 
aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells two times per week for 
5 weeks 
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aerosol IL-2, aerosol PBS + human NK cells or aerosol IL-2 + human NK cells 6 
weeks after LM7 injection. Aerosol therapy was continued every other day for 5 
weeks. NK cell injections (5 x 107 cells/mouse) were given 2 times a week 
starting 1 day after the first aerosol treatment. Following the treatment, the mice 
were sacrificed and the lungs resected for further analysis (Figure 10).  
RESULTS 
Aerosol IL-2 + NK cell therapy decreases the number of pulmonary 
metastatic nodules 
 Aerosol IL-2 + NK cell therapy significantly decreased the number of 
pulmonary metastatic nodules, when compared to control (aerosol PBS) (P = 
0.01), aerosol IL-2 alone (P = 0.03) and aerosol PBS + NK cells (P = 0.01) 
(Figure11). Four mice treated with aerosol IL-2 + NK had no visible metastasis 
present in the lung. In comparison, only one of the mice treated with aerosol PBS 
+ NK cells had no visible pulmonary metastasis (Figure 12). The mean number of 
pulmonary metastatic nodules present in mice treated with both aerosol IL-2 and 
NK cells was 2.8 ± 1.6, compared to 13 ± 3 nodules for aerosol PBS + NK cell 
treated mice, 18.4 ± 5.4 nodules for aerosol IL-2 treated mice and 22.6 ± 6 
nodules present in aerosol PBS treated mice. Both aerosol IL-2 alone and 
aerosol PBS + NK cell treatments decreased the mean number of metastatic 
lung nodules, but the decrease was not statistically significant when compared to 
aerosol PBS treatment (P = 0.6 and P = 0.1, respectively).  
38

 
Figure 11: Aerosol IL-2 + NK cell therapy decreases the number of 
pulmonary metastatic nodules. Nude mice were injected i.v. with 3 X 10
6
 
LM7 cells. Therapy was initiated 6 weeks later. Mice were treated with 
aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK 
cells for five weeks. Mice were sacrificed, their lungs harvested and the 
mean number of metastatic nodules was determined. P < 0.05 was 
considered significant. Figure and figure legend were originally published 
in Pediatric Blood and Cancer 2013. This material is reproduced with 
permission of John Wiley & Sons, Inc.. 
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Aerosol IL-2 + NK cell therapy decreases the size of pulmonary metastatic 
nodules 
 Aerosol IL-2 + NK cell therapy significantly decreased the size of the 
individual lung tumor nodules (Figure 13). The mean diameter of lung nodules in 
mice treated with aerosol IL-2 + NK cells was 1.12 mm ± 0.36, compared to 2.07 
mm ± 0.46 for  those treated with aerosol PBS (P = 0.005) and 1.9 mm ± 0.42 for 
those treated with aerosol IL-2 (P = 0.004). Aerosol IL-2 therapy alone did not 
*Novisiblepresenceofmacrometastasis 
* * * *
*
AerosolPBS 
AerosolILͲ2 
AerosolPBS
+ 
NKCells 
AerosolILͲ2
+ 
NKCells 
Figure 12: Representative picture of lungs of mice treated with aerosol PBS, 
aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 + NK cells for five weeks. 
Nude mice were injected i.v. with 3X10
6
 LM7 cells. Therapy was initiated 6 weeks 
later. Mice were sacrificed and their lungs harvested. Figure and figure legend were 
originally published in Pediatric Blood and Cancer 2013. This material is reproduced 
with permission of John Wiley & Sons, Inc.. 
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reduce the mean tumor diameter when compared to aerosol PBS (P = 0.8). 
Aerosol PBS + NK cell therapy did seem to decrease tumor size, from a mean 
tumor diameter of 2.07 mm ± 0.46 for those treated with aerosol PBS to 1.37 mm 
± 0.43. Yet, this decreases was not statistically significant (P = 0.07). The mean 
tumor diameter was not statistically significant between aerosol IL-2 + NK cell 
and aerosol PBS + NK treated mice (P = 0.4).  
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Figure 13: Aerosol IL-2 + NK cell therapy reduces pulmonary metastatic nodule 
size. Nude mice were injected i.v. with 3X10
6
 LM7 cells. Mice were treated with aerosol 
PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells for five weeks. Mice 
were sacrificed, their lungs harvested and the diameter of each individual tumor nodule 
was measured. P < 0.05 was considered significant. Figure and figure legend were 
originally published in Pediatric Blood and Cancer 2013. This material is reproduced with 
permission of John Wiley & Sons, Inc..
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Aerosol IL-2 + NK Cell therapy decreases the total surface area of the lung 
that was infiltrated with osteosarcoma metastasis 
 The surface area of each tumor nodule was calculated. The total surface 
area of each lung that was infiltrated with metastasis was calculated by the sum 
of the surface areas of each of its individual tumor nodules. From these values, 
the mean total metastatic area was calculated for each treatment group. Aerosol 
IL-2 + NK cell therapy significantly reduced the total area of the lungs covered in 
metastases compared to that of mice treated with aerosol PBS (P =0.004), 
aerosol IL-2 (P = 0.04) or aerosol PBS + NK cells (P= 0.05) (Figure 14).  
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Figure 14: Aerosol IL-2 + NK cell therapy decreases the total area of lungs infiltrated 
with osteosarcoma metastasis. Nude mice were injected i.v. with 3 X10
6
 LM7 cells. Mice 
were treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK 
cells for five weeks. Mice were sacrificed, their lungs harvested and the total metastatic area 
was calculated. P < 0.05 was considered significant. Figure and figure legend were originally 
published in Pediatric Blood and Cancer 2013. This material is reproduced with permission 
of John Wiley & Sons, Inc.. 
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Aerosol IL-2 + NK Cell therapy increased tumor apoptosis 
 NK cell killing is mediated by the secretion of cytotoxic granules that 
trigger the apoptotic pathway [28]. We have demonstrated that aerosol IL-2 + NK 
cell therapy significantly reduced metastatic tumor burden. TUNEL staining was 
used to evaluate if this were due to increased apoptosis in the tumor nodules 
(Figure 15). Apoptosis was significantly higher in lung metastases from the mice 
treated with aerosol IL-2 + NK cells when compared to mice treated with aerosol 
PBS (P =0.009), aerosol IL-2 (P= 0.02) or aerosol PBS + NK cells (P= 0.05). 
Aerosol IL-2 and PBS + NK cells also increased tumor apoptosis when compared 
to aerosol PBS treatment. However, though the mean of aerosol IL-2-induced 
apoptosis was lower than that induced by aerosol PBS + NK cell therapy, its 
increase was statistically significant when compared to aerosol PBS (P = 0.003), 
while the increase induced byaerosol PBS + NK cells was not statistically 
significant (P = 0.17).   
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
Tumor apoptosis inversely correlates with the amount and size of 
pulmonary metastatic nodules.  
 To further corroborate that the increase in apoptosis is associated with the 
decrease in pulmonary metastatic burden, TUNEL values for each lung were 
Figure 15. Aerosol IL-2 + NK cell therapy increased tumor apoptosis.  Mean 
positive TUNEL was quantified using the Simple PCI software in 5 random fields 
per section. P < 0.05 was considered significant. Figure and figure legend were 
originally published in Pediatric Blood and Cancer 2013. This material is 
reproduced with permission of John Wiley & Sons, Inc.. 
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correlated to the corresponding number of metastatic nodules, mean diameter of 
nodules, and total metastatic area using a Spearman Rank correlation (Figure 
16). The level of apoptosis inversely correlated with tumor burden, as quantified 
by the number of metastases (R = -0.788, P = 0.008), tumor diameter (R = -0.89, 
P = 0.008) and metastatic area (R = -0.78, P = 0.0009). This inverse correlation 
was validated by a linear regression analysis.  
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Figure 16. Tumor apoptosis inversely 
correlates with pulmonary metastatic 
burden TUNEL Simple PCI quantified 
values for each lung were correlated to 
the corresponding number of metastatic 
nodules, mean diameter of nodules, and 
total metastatic area. P < 0.05 was 
considered significant. Figure and figure 
legend were originally published in 
Pediatric Blood and Cancer 2013. This 
material is reproduced with permission of 
John Wiley & Sons, Inc.. 
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SUMMARY 
Combination therapy with aerosol IL-2 and NK cells significantly reduced 
pulmonary osteosarcoma metastasis, as measured by the number of tumors, the 
size of the metastatic nodules and by the metastatic infiltration of the lung.  This 
was accompanied by a significant increase in tumor apoptosis. Tumor apoptosis 
inversely correlated with tumor number, tumor size, and metastatic infiltration. 
These results suggest that increased apoptosis is the mechanism behind the 
observed reduction in metastasis. This was expected, as NK cells kill by 
releasing cytotoxic granules that trigger the apoptotic pathway [28].   
Giving aerosol IL-2 increases the efficacy of NK cell therapy against 
osteosarcoma lung metastasis. Our hypothesis was proven correct by the 
significant greater reduction in metastasis and increased tumor killing when 
aerosol IL-2 was given with NK cells versus to giving aerosol PBS with NK cells. 
Monotherapy with aerosol IL-2 slightly reduced tumor numbers and increased 
tumor killing, but to a much lesser degree.  
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Chapter 6 
Aerosol IL-2 increased the NK cell infiltration of osteosarcoma metastasis 
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RATIONALE 
 We have shown that aerosol IL-2 increases the efficiency of NK cell 
therapy, as demonstrated by a reduction in osteosarcoma lung metastasis. This 
reduction is correlated with increased tumor apoptosis. Since aerosol IL-2 
increases the presence of injected NK cells inside normal mouse lungs and NK 
cells kill primarily by activating tumor cell apoptosis [28], we hypothesized that 
aerosol IL-2 increased the number of NK cells inside the tumor nodules, thereby 
facilitating the physical interaction between the NK cells and their targets.  
 In this chapter we evaluated the infiltration of lung tumor nodules by 
human NK cells through the use of immunofluorescence staining. We also 
evaluated the presence of mouse NK cells in the same tumor nodules.  
RESULTS 
Aerosol IL-2 increased human NK cells in the metastatic osteosarcoma 
nodules in the lung 
 Fluorescent microscopy demonstrated increased human NKG2D staining 
in the lung metastasis from mice treated with aerosol IL-2 + human NK cells 
versus that from the mice treated with aerosol PBS + human NK cells (P = 0.038; 
Figure 17). Thus, aerosol IL-2 increases the contact between injected NK cells 
and their target tumor 
50
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cells.
.  
 
Figure 17. Aerosol IL-2 increased human NK cells in lung metastasis.  
Fluorescent microscopy was used to determine the NK cell infiltration in the lung 
using anti-human NKG2D (red). Cellular nuclei were identified with Hoechst33258 
(blue). Mean positive fluorescence was quantified using the Simple PCI software in 
5 random fields per section. P < 0.05 was considered significant. Figure and figure 
legend were originally published in Pediatric Blood and Cancer 2013. This material 
is reproduced with permission of John Wiley & Sons, Inc..
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Aerosol IL-2 increased mouse NK cells in the metastatic osteosarcoma 
nodules in the lung 
 Fluorescent microscopy demonstrated increased mouse NKp46 staining in 
the lung metastasis from mice treated with aerosol IL-2 versus that from mice 
treated with aerosol PBS (P = 0.05, Figure 18). This demonstrates that aerosol 
IL-2 therapy also increases the number of the mice’s own NK cells inside the 
tumor. However the presence of mouse NK cells in the lung metastasis was 
much lower than the presence of human NK cells. Whether this contributes to 
aerosol IL-2’s overall therapeutic effect is unknown. The number of mouse NK 
cells was also increased inside metastasis which were given aerosol IL-2 + 
human NK cells when compared to aerosol PBS treated mice (P = 0.013). 
However, there wasn’t any statistically significant difference in the number of 
mouse NK cells present in the lung when comparing aerosol PBS + human NK 
cell-treated mice versus aerosol IL-2 treated mice and when comparing aerosol 
PBS + NK cell--treated mice versus aerosol IL-2 + human NK cell-treated mice 
(P = 0.1 and P = 0.23, respectively). NK cells are known to release a variety of 
cytokines and immune stimulators, such as INFȖ and MIP-1Į, both of which are 
potent macrophage activators [17]. Activated monocytes/macrophages can 
themselves secrete cytokines that activate NK cells [17]. There is a possibility 
that the injected human NK cells activate the mice’s monocytes/macrophages, 
which would in turn stimulate the mice’s own NK cells. There was no significant 
difference in the amount of mouse NK cells inside the lung metastasis when we 
compared aerosol IL-2 versus aerosol IL-2 + human NK cell treated mice (P = 
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0.2) and when we compared aerosol PBS versus aerosol PBS + human NK cell 
treated mice (P = 0.2).  
 
 
 
Figure 18. Aerosol IL-2 increased mouse NK cells in lung metastasis.  Fluorescent 
microscopy was used to determine the NK cell infiltration in the lung using anti-mouse 
NKp46 (red). Cellular nuclei were identified with Hoechst33258 (blue). Mean positive 
fluorescence was quantified using the Simple PCI software in 5 random fields per 
section. P < 0.05 was considered significant. 
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SUMMARY 
 We have demonstrated that aerosol IL-2 increases the number of NK cells 
inside pulmonary osteosarcoma metastasis. This explains why combining NK cell 
therapy with aerosol IL-2 increases its effectiveness against osteosarcoma lung 
metastasis. A larger number of injected NK cells come into contact with their 
target tumor, increasing apoptosis and thus reducing lung metastasis. We have 
also demonstrated that aerosol IL-2 increases the number of mouse NK cells 
inside the tumor nodules. Whether direct killing of the human tumor cells by 
mouse NK cells contributes to aerosol IL-2’s therapeutic efficacy is a matter of 
debate. Mouse NKG2D and human NKG2D recognize different ligands, with 
limited amino acid sequence homology among them [60]. However, even if 
mouse NK cells aren’t directly responsible for the killing, they can still be 
activated by human IL-2 [72]. Consequently, they might in turn secrete other 
immune activating cytokines. For example, IL-2 activated NK cells secrete INFܵ, 
TNFĮ, MIP-1Įȕ, and GM-CSF, all of which stimulate macrophages [16]. 
Activated macrophages may be responsible for attacking the osteosarcoma cells.  
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Chapter 7 
Aerosol IL-2 + NK cell therapy increased the overall survival of mice with 
osteosarcoma lung metastasis 
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RATIONALE 
 
 We have demonstrated that aerosol IL-2 + NK cell therapy reduces 
pulmonary metastatic burden, as measured by a decrease in tumor numbers and 
size, as well as an increase in tumor apoptosis. One of the main goals for this 
investigation was to provide pre-clinical data to support moving forward with a 
clinical trial. To further test aerosol IL-2 + NK cell’s potential as a therapeutic, we 
designed a study to determine whether treatment with aerosol IL-2 + NK cells 
increases overall survival.  
 3 million LM7 cells/mouse were injected intravenously through the tail vein 
of nu/nu mice. Once micro-metastasis was confirmed, treatment was initiated 
with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells 
and was continued for 5 weeks. Aerosol treatment was given 3 times per week. 
50 million human NK cells/mouse were injected through the tail vein 2 times per 
week. We then proceeded to determine the overall survival for the mice in the 
four treatment groups. We ended the survival study 162 days after starting 
treatment. Mice that had survived until this moment were euthanized. Long term 
survival was assessed from the first day of treatment until death.  
RESULTS 
Aerosol IL-2 + NK cells increased the overall survival of mice with 
osteosarcoma lung metastasis 
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 Aerosol IL-2 + NK cell therapy significantly increased the overall survival 
of mice with osteosarcoma lung metastasis (Figure 19B). Mice treated with 
aerosol PBS had a median survival of 71 days, while aerosol IL-2 + NK cell 
treated mice had a median survival of 130 days (P = 0.0153). By day 94 all the 
control mice were dead. 40% of the aerosol IL-2 + NK cell treated mice survived 
to the end of the study.  
Treatment with aerosol IL-2 also increased the survival of mice with 
osteosarcoma lung metastasis (Figure 19C). Aerosol IL-2 increased the median 
survival from 71 days to 89 days (P = 0.03). Three aerosol IL-2-treated mice 
survived until the end of the study. The median survival of aerosol PBS + NK cell-
treated mice was 109.5 days, higher than either the median survival of aerosol 
IL-2-treated or aerosol PBS-treated mice. Yet, because 3 aerosol PBS + NK cell-
treated mice died very early in the study, the increase in overall survival was not 
significant when compared to control (P = 0.06; Figure 19D).  
 The median survival of mice treated aerosol IL-2 + NK cells was higher 
than those treated with aerosol IL-2 (Figure 19E) and those treated with aerosol 
PBS + NK cells (Figure 19F). However, the difference in overall survival was not 
significant (P = 0.7, P = 0.57, respectively). This was due to the increased life-
span provided by aerosol PBS + NK cells and aerosol IL-2 treatment, though not 
as much as that provided by aerosol IL-2 + NK cells therapy.  
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 As demonstrated in Figure 20, most of the mice that survived for 162 days 
did not have any visible metastasis present. Only one lung demonstrated the 
presence of metastasis. It belonged to a mouse treated with aerosol IL-2. This 
mouse only had one metastatic nodule with a diameter of less than1.3 mm. This 
demonstrates that treatment with aerosol IL-2, aerosol PBS + NK cells or aerosol 
Figure 19. Effect of aerosol IL-2, NK cell therapy, and aerosol IL-2 + NK cells on 
the overall survival of mice with osteosarcoma lung metastasis. Nude mice were 
injected intravenously with LM7 cells. Therapy was initiated 6 weeks later and 
continued for 5 weeks. Mice were euthanized when they became moribund or after 
162 days. a. Long-term survival was assessed from the first day of treatment. Overall 
survival of mice treated with aerosol IL-2 + NK cells (b), aerosol IL-2 (c) and aerosol 
PBS + NK cells (d) were compared to with those of aerosol PBS-treated mice.  The 
overall survival of mice treated with aerosol IL-2 + NK cells was also compared with 
that of mice treated with aerosol IL-2 alone (e) or aerosol PBS + NK cells (f). The log-
rank test was used to determine statistical significance. P < 0.05 was considered 
significant 
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IL-2 + NK cells not only decreased tumor burden and increased survival, but 
were also capable of eliminating metastasis. We could say that macroscopically, 
40% of the mice treated with aerosol IL-2 + NK cells were cured of the 
malignancy, while 30 % of the mice treated with aerosol PBS + NK cells and 20% 
of the mice treated with aerosol IL-2 were cured of malignancy.  
 
Figure 20: Representative picture of lung harvested from treated mice that 
were alive at the end of the study. Nude mice were injected i.v. with 3X10
6
 LM7 
cells. Therapy was initiated 6 weeks later. Mice were treated with aerosol IL-2, 
aerosol PBS + NK cells or aerosol IL-2 + NK cells for five weeks. Long-term 
survival was assessed from the first day treatment was initiated. Mice were 
euthanized when they became moribund and after 162 days.  
 
SUMMARY 
AerosolILͲ2 
AerosolPBS
+ NK Cells
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 Our results demonstrate that aerosol IL-2 + NK cell therapy significantly 
increased the survival of mice with osteosarcoma lung metastasis. Treatment 
with aerosol IL-2 also significantly increased survival. However, the increase was 
less significant and to a lesser degree. Aerosol IL-2 + NK cell therapy increased 
the median survival from 71 days to 132 days. This median survival was higher 
than the survival seen in the other 2 treatment groups, though the difference was 
not significant. 40% of mice treated with aerosol IL-2 + NK cells survived the 
study at 162 days, with no macroscopic evidence of disease. 30% of mice 
treated with aerosol PBS + NK cells survived for 162 days, with no macroscopic 
evidence of disease. 30% of the mice treated with aerosol IL-2 survived for 162 
days, with one of the mice demonstrating macroscopic evidence of disease. All 
the control mice had died by day 94.  
 The survival of the mice treated with aerosol IL-2 + NK cells was higher 
than that of the mice treated with aerosol IL-2 or NK cells alone. However, the 
difference in survival was not statistically significant. This was due to the ability of 
monotherapy with either aerosol IL-2 or NK cells to increase survival. In order to 
observe significance between the overall survivals between these treatment 
groups, a future experiment would be developed in which we extend the survival 
study beyond 162 days. As demonstrated in Figure 20, none of the lungs of the 
surviving mice treated with aerosol IL-2 + NK cells had evidence of macroscopic 
disease, while one mouse treated with aerosol IL-2 alone had macroscopic 
disease in the lung. In all probability, this mouse would have died if the study had 
been extended.  A true survival study would be waiting until all of the mice in 
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each treatment group died, or until we could establish significant difference 
between the groups. If statistical significance could not be established, we would 
repeat the experiment starting treatment at earlier or later time points. The 
effectiveness of NK cell therapy is dependent on tumor size. Choosing a different 
time point to start treatment would mean treating lung nodules of greater or 
smaller sizes. This can translate into finding the difference in therapeutic efficacy 
between the three treatment modalities.  
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Chapter 8 
Toxicity of aerosol IL-2 therapy 
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RATIONALE 
 One of the main reasons behind the use of aerosol IL-2 is to avoid the 
toxicities associated with systemic IL-2 treatment. The safety of aerosol IL-2 has 
been well documented in clinical trials [52, 55, 73]. Reversible airway irritation 
that causes non-productive coughing has been documented as the dose-limiting 
toxicity for aerosol IL-2 [55]. This side effect is much more tolerable compared to 
the high grades fevers, malaise, and fatigue normally associated with IL-2 
treatment. In addition, it does not have the potential for the development of 
vascular leak syndrome, which has been reported to have caused respiratory 
failures in certain cases [74]. Patients report a much better quality of life, 
compared to systemic IL-2 treatments [52]. This lack of systemic toxicities is 
associated to very low IL-2 serum increases observed during aerosol treatment, 
with IL-2 levels peaking to just 1% of those observed after i.v. bolus injections 
[55, 75].  
 In this chapter, we describe how we evaluated aerosol IL-2 toxicity. Both 
Nu/Nu and BALB/C mice were used. BALB/C mice were used because of their 
immunocompetence. The lack of T-cells in Nu/Nu mice makes this model 
insufficient to represent aerosol IL-2-indued side effects. Nu/Nu mice had to be 
used to investigate NK cell associated toxicities because immunocompetent mice 
reject human NK cells.  
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RESULTS 
Aerosol IL-2 does not cause acute or chronic toxicities in 
immunocompetent mice as evaluated by histological examination 
 BALB/C mice were treated with either aerosol IL-2 or aerosol PBS every 
other day for one week. Mice were sacrificed three days and one week after the 
start of the aerosol treatment to investigate acute toxicity. They were also 
sacrificed one month after the end of treatment. Lungs, spleens, livers, hearts 
and kidneys were fixed in formalin and embedded in paraffin. Corresponding 
H&E stained slides were analyzed with the help of Dr. John Stewart (Department 
of Pathology, MD Anderson Cancer Center). We did not find any histological 
evidence for acute or chronic inflammation, scarring or toxicity in the lungs, 
spleen, liver, heart or kidney of either the aerosol PBS or aerosol IL-2 treated 
mice (Figure 21).  
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Aerosol IL-2, NK cell therapy or aerosol IL-2 + NK cell therapy does not 
cause acute or chronic toxicities in nu/nu mice as evaluated by histological 
examination 
Figure 21: Aerosol IL-2 does not cause acute or chronic inflammation, scarring or 
toxicity. Representative H&E stained slides of lung, spleen, liver, heart and kidney of 
BALB/C mice treated with aerosol PBS or aerosol IL-2 for one week. Mice were euthanized 
either three days or one week after start of treatment, or one month after the end of 
treatment. Pictures shown were obtained from those mice sacrificed one month after the end 
of treatment. Figure and figure legend were originally published in Pediatric Blood and 
Cancer 2013. This material is reproduced with permission of John Wiley & Sons, Inc.. 
AerosolPBS 
Lung Spleen Liver Heart Kidney 
AerosolILͲ2 
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 Nu/Nu mice were treated for one week with aerosol PBS + NK cells or 
aerosol IL-2 + NK cells. Mice were euthanized one day, three days and one week 
after NK cell injection. Lungs, spleens, livers, hearts and kidneys were stained 
with H&E and analyzed with the help of Dr. John Stewart (Department of 
Pathology, MD Anderson Cancer Center). No histological evidence of acute 
inflammation, scarring or toxicity was found. Nu/Nu mice with LM7 metastasis 
were treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells and aerosol 
IL-2 + NK for 5 weeks. Mice were euthanized at the 5th week after start of 
treatment.  Lungs, spleens, livers, hearts and kidneys were stained with H&E and 
analyzed with the help of Dr. John Stewart (Department of Pathology, MD 
Anderson Cancer Center). No histological evidence of chronic inflammation, 
scarring or toxicity was found. 
Aerosol IL-2 therapy does not alter complete blood count or liver enzyme 
chemistry 
 The complete blood count [CBC] of mice with LM7 metastasis that had 
been treated with aerosol IL-2 or aerosol PBS for two and five weeks was 
determined (Figure 22 A, B). Aerosol IL-2 therapy did not alter CBC values. This 
suggests that aerosol IL-2 does not produce a significant systemic inflammation. 
Liver enzyme chemistry levels of the same mice treated for five weeks were also 
examined (Figure 22C). No significant changes in liver enzyme chemistry were 
found, suggesting aerosol IL-2 does not induce liver damage. Alkaline 
phosphatase was increased in aerosol PBS and aerosol IL-2 treated mice when 
compared to normal mouse basal levels. This was expected because alkaline 
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phosphatase levels are increased in patients with osteosarcoma, and is 
associated with worse prognosis [76].  
 
Figure 22: Aerosol IL-2 does not alter CBC or Liver Enzyme Chemistry: 
Mice were treated with aerosol PBS or aerosol IL-2 for 2 (A) or 5 weeks (B) 
and their CBC was determined. C. Liver enzyme chemistry was determined 
after 5 weeks of treatment. Basal mouse levels for CBC and liver enzyme 
chemistry are shown. P< 0.05 was considered significant. 
A
B
C
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Serum IL-2 levels following aerosol IL-2 treatment 
 Serum IL-2 levels were measured in mice treated with aerosol IL-2 
2 times per week for 2 and 5 weeks. Aerosol PBS treatment was used as the 
negative control. The positive control was serum from mice treated with a single 
dose of 20,000U IL-2 i.p, the dose normally used in therapeutic studies 
evaluating adoptive cellular therapy [77]. Aerosol IL-2 given for 2 weeks did not 
significantly increase serum IL-2 levels compared to aerosol PBS (P = 0.3). While 
aerosol IL-2 given for 5 weeks resulted in mild elevations in serum IL-2 
(P=0.012), these levels were significantly lower than the IL-2 levels measured in 
mice treated with a single dose of 20,000 U IL-2 i.p. (Figure 23) (Originally 
published in Pediatric Blood and Cancer 2013. This material is reproduced with 
permission of John Wiley & Sons, Inc.) These very low increases in serum IL-2 
caused by aerosol IL-2 explain the lack of systemic side effects associated with 
aerosol IL-2, as well as the fact that aerosol IL-2 therapy did not increase the 
number of injected human NK cells in extra-pulmonary organs. It further 
strengthens the argument that aerosol IL-2 therapy is localized and organ-
specific.  
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Figure 23: Serum IL-2 levels after aerosol IL-2 treatment: ELISA was used to determine 
serum IL-2 for mice treated with aerosol PBS, aerosol IL-2 for 2 weeks, aerosol IL-2 for 5 
weeks and 1 dose of 20,000U IL-2 i.p.  P < 0.05 was considered significant. Figure and figure 
legend were originally published in Pediatric Blood and Cancer 2013. This material is 
reproduced with permission of John Wiley & Sons, Inc.. 
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Neither aerosol IL-2 nor NK cell therapy induces weight change in mice 
 To further corroborate that aerosol IL-2 is non-toxic, we monitored the 
weight of mice with LM7 lung metastasis treated for five weeks with either 
aerosol PBS, aerosol IL-2, aerosol PBS + NK cells, or aerosol IL-2 + NK cells. 
Weight change was monitored from the moment the treatment was initiated to 
one week after the treatment was stopped. As a control, we also monitored the 
weight change of a group of similarly aged mice for a period of 6 weeks.  All mice 
experienced weight gain during a period of 6 weeks. However, there was no 
significant difference between the weights gained by the 5 groups (Figure 24). 
The mice that had no metastasis and received no treatment, gained an average 
of 2.07 g ± 0.6. This weight gain is not significantly different from the average 
weight gained by those with metastasis and treated with aerosol PBS (1.6 g ± 
0.93; P = 0.748), aerosol IL-2 (2.62 g ± 0.8, P = 0.564), aerosol PBS + NK cells 
(2.47 g ± 1.37, P = 0.773) and aerosol IL-2 + NK cells (2.6 g ± 0.565; P = 0.96). 
In addition, the weight gain experienced by aerosol PBS treated mice was not 
significantly different from that experienced by mice treated with aerosol IL-2 (P = 
0.4), aerosol PBS + NK cells (P = 0.6) and aerosol IL-2 + NK cells (P = 0.4).  
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SUMMARY 
 In this chapter we established the safety of aerosol IL-2 therapy, NK cell 
therapy and aerosol IL-2 + NK cell therapy. Histological examination of the 
spleen, lung, liver, heart and kidney of mice treated with aerosol lL-2, aerosol 
Figure 24. Weight gain during treatment. The weights of mice with LM7 metastasis 
and treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 + 
NK cells for 5 weeks were monitored. The weight of untreated mice without lung 
metastasis was monitored as a control. P<0.05 was considered significant.  
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PBS + NK cells or aerosol IL-2 + NK cells showed no signs of acute or chronic 
inflammation, scaring, or toxicity. There weren’t any treatment associated weight 
changes. Furthermore, aerosol IL-2 treatment did not alter the complete blood 
count or the liver enzyme chemistry. This establishes that aerosol IL-2 treatment 
is organ specific and does not induce an altered systemic inflammatory state. 
Systemic IL-2 is known to be able to cause leukopenia and rebound 
lymphocytosis [78], neither of which was suggested by the complete blood count. 
Other toxicities associated with systemic IL-2 that could be represented by a 
complete blood count include thrombocytopenia and anemia [79]. In addition, IL-
2 can cause hepatic toxicity [79], which would present as increased serum liver 
enzymes. We also established that aerosol IL-2 can cause a small but significant 
increase in serum IL-2 levels if given for 5 weeks every other day. However, 
these levels are below those found in mice treated with intraperitoneal IL-2. This 
explains the lack of systemic side effects associated with aerosol IL-2 treatment 
and the reason why aerosol IL-2 increased NK cell numbers in the lung, but not 
in other organs. This suggests aerosol IL-2 activity is organ-specific.  
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Discussion: Implications of Results and Future Directions 
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 The 5-year survival rate for patients with osteosarcoma has plateaued at 
60-70% using combination chemotherapy and surgery.  With the exception of L-
MTP-PE, no new drugs have been developed for either newly diagnosed or 
relapsed osteosarcoma in 20 years [10]. The primary cause of death is 
respiratory failure due to metastatic burden [2], as the lung is the most frequent 
site of metastatsis. Lung osteosarcoma metastasis has a very bad prognosis, 
with a 5 year survival of 33% [5]. Survival is even lower for relapsed patients. 
Less than 20% of relapse patients survive [6]. Moreover, salvage chemotherapy 
following relapse has been shown to slow disease progression but has no impact 
on long-term survival [80]. This implies the development of chemotherapy 
resistance.  For this reason, we must look beyond traditional chemotherapeutics 
for the treatment of primary and recurrent osteosarcoma lung metastasis.  
 As mentioned before, L-MTP-PE is the first new agent approved for the 
treatment of osteosarcoma in the last 20 years [10]. Adding L-MTP-PE to 
standard chemotherapy for primary osteosarcoma increases the 6-year survival 
from 70 to 78% [9]. L-MTP-PE activates the tumoricidal properties of pulmonary 
macrophages and peripheral blood monocytes. The success of L-MTP-PE in 
increasing survival paves the way for the development of other immunotherapies 
to target osteosarcoma lung metastasis. Our laboratory previously showed that 
the intravenous injection of IL-11RĮ-CAR+ T-cells resulted in the regression of 
osteosarcoma lung metastases in a nude mouse model [11]. These findings 
further support the potential benefit of immunotherapy in the treatment of this 
malignancy. One of the drawbacks of IL-11RĮ-CAR+ T-cell therapy is the 
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collateral organ toxicity to those organs that express the IL-11 RĮ.  IL-11 RĮ is 
expressed in the liver, stromal tissues of the GI tract, surface and gland epithelial 
cells, and on endothelial cells.  By contrast, NK cells are a component of the 
innate immune system that recognize and kill malignant and virally infected cells 
but not normal host cells. Therefore the therapeutic: toxicity index is expected to 
be much higher. 
NKG2D ligand expression in osteosarcoma 
NKG2D ligands were highly expressed in both osteosarcoma cell lines 
(Figure 1) and patient tumor specimens (Figure 4). NKG2D is the major 
activating receptor on NK cells. The NKG2D ligand status determines the 
effectiveness of NK-cell based immunotherapies [58, 62]. These results suggest 
that osteosarcoma is a good target for NK cell therapy. Among the patient 
samples, a greater percentage of cells expressed NKG2D ligands in pulmonary 
metastases (77%) than in the primary tumors (57%). This validates the potential 
of NK cell therapy for relapsed disease in the lungs. NK killing assays further 
corroborated osteosarcoma’s susceptibility to NK cells. It also demonstrated that 
the magnitude of in vitro killing correlated with the levels of NKG2D ligand 
expression (Figure 2). With the exception of KRIB cells, NK cytotoxicity against 
human osteosarcoma cells was 40 -50% at 1:1 E:T ratios. NK cytotoxicity against 
KRIB cells was near 10% at 1:1 E:T ratios. This reduced cytotoxicity correlated 
with the lower expression of NKG2D ligands found on KRIB cells when compared 
to the other cell lines (Figure 8). Conversely, NK cytotoxicity was significantly 
decreased when the NKG2D- NKG2D ligand interaction was blocked. This 
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demonstrates that NK-mediated killing of osteosarcoma is dependent on NKG2D 
ligand expression. It also suggests the effectiveness of NK cell therapy could be 
predicted based upon the patients’ specific osteosarcoma NKG2D ligand 
expression. 
Aerosol IL-2 increases NK cells in the lung 
One of main purposes of using concomitant aerosol IL-2 was to increase 
the number of injected NK cells in the lung in order to facilitate their therapeutic 
potential against pulmonary osteosarcoma lung metastasis. We demonstrated 
that, while intravenous injection of fluorescent-labeled NK cells resulted in some 
localization in the lung, aerosol IL-2 significantly increased the number of NK 
cells in the lung three days post-injection (Figure 5). This increased localization 
of labeled NK cells was organ specific, as the number of NK cells was not 
increased in the liver, spleen, heart or kidney (Figure 6). In both aerosol PBS and 
aerosol IL-2 treated mice almost no human NK cells localized in the heart or 
kidney, while a very large amount were found present in the liver and spleen. 
These data is consistent with studies studying organ distribution of allogeneic NK 
cells in human patients [45]. Thirty minutes after transfusion, allogeneic NK cells 
aggregate in the lung. Two hours post transfusion they redistribute to the rest of 
the body, concentrating in the spleen, liver and bone marrow.  
We determined the increase in the number of NK cells in the lung is 
caused by an increase in proliferation. Aerosol IL-2 significantly increases the 
percentage of proliferating NK cells in the lung (Figure 7), but not in the spleen or 
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liver (Figure 9). It slightly increases the proliferation of NK cells in the bone 
marrow 24 hours post injection, but not at 72 hours post injection (Figure 8). The 
increase in NK proliferation in the lung was greatest 72 hours after injection. This 
correlates to the time point in which we see the largest increase of NK cell 
numbers in the lung. This shows that the central site for aerosol IL-2 induced 
proliferation is the lung. On the other hand, intranasal respiratory virus infection 
induces NK proliferation in the bone marrow, not in the lung [71]. The increase of 
NK numbers in the lung is a result from migration from the bone marrow.  
Aerosol IL-2 does not increase NK cell numbers or proliferation in extra 
pulmonary organs because aerosol IL-2 treatment for less than two weeks does 
not increase serum IL-2 levels (Figure 27). This suggests that the IL-2 from 
aerosol concentrates in the lung, with little spill over to the periphery.  
Aerosol IL-2 increased the efficacy of NK cells in vivo 
 Aerosol IL-2 also increases the number of injected NK cells present in the 
metastatic pulmonary nodules (Figure 17). We have already shown that NK 
killing of osteosarcoma is dependent on the E: T ratio (Figure 2). Having an 
increased presence of NK cells inside the tumor should translate into an 
increased therapeutic efficiency. NK-killing is mediated by the release of 
cytotoxic granules that trigger the apoptotic pathway [81]. The addition of aerosol 
IL-2 to NK cell therapy significantly increased the degree of apoptosis present in 
the tumor nodules (Figure 15). These increased levels of apoptosis correlated 
with decreased overall metastatic burden, as measured by tumor numbers and 
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tumor size (Figure 11- 14). Higher NK cell numbers contributed to increased 
tumor apoptosis, which translated into a better therapeutic outcome. However, 
aerosol IL-2’s may also improve NK therapy by other mechanisms. IL-2 is known 
to increase the expression of NKG2D and NCR receptors. This makes NK cells 
more sensitive to activating ligands, which increases cytotoxicity and cytokine 
secretion [82].  IL-2 treatment can enhance NK adhesion and killing against weak 
targets, i.e., those who express low levels of activating ligands [83]. IL-2 also 
enhances F-actin reorganization in NK cells, necessary for cytotoxic granule 
release [84]. Aerosol IL-2 could have also increased the NK therapeutic efficacy 
by directly enhancing cytotoxicity in addition to increasing their proliferation.  
 Aerosol IL-2 also increased the number of mouse NK cells in metastatic 
pulmonary nodules (Figure 18). Whether this contributed to the therapeutic 
outcome is unknown. Monotherapy with aerosol IL-2 significantly increased 
tumor apoptosis (Figure 15). It also decreased tumor number and tumor size 
(Figure 11-14), though not significantly. However, it did increase mean survival 
(Figure 20). Mouse NKG2D and human NKG2D recognize different substrates, 
and there is little sequence homology among these [60]. It is unlikely that the 
observed increased tumor apoptosis was due to direct killing by mouse NK cells. 
However, mouse NK cells can be activated by human IL-2 [85]. Activated NK 
cells are known to secrete a variety of cytokines that influence other members of 
the immune system. For example, they release potent macrophage activators, 
such as INFȖ and MIP-1Į [17]. They can also kill M0 and M2 macrophages, but 
spare M1 macrophages [86]. This may suggest that IL-2 activated mouse NK 
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cells could have increased tumor apoptosis by enhancing the tumoricidal 
properties of the macrophage population in the lung. NK cells also interact with T 
cells and dendritic cells [16], but this interaction is not relevant  in our 
investigation because our mouse model was athymic. NK cells are also able to 
kill endothelial cells [87]. The vasculature present in LM7 osteosarcoma 
metastasis is of mouse origin. Mouse tumor vasculature expresses NKG2D 
ligands [88]. This implies that tumor apoptosis could have been increased by a 
reduced blood flow caused by mouse NK-mediated killing of tumor vasculature. 
Aerosol IL-2 + NK cell therapy increased overall survival 
 The enhanced tumor regression conferred by aerosol IL-2 + NK cell 
therapy rendered an increase in overall survival in mice with osteosarcoma lung 
metastasis (Figure 19B). Surprisingly, we also observed that monotherapy with 
aerosol IL-2 increased overall survival (Figure 19C). This may be due to an 
indirect activation of other immune cells in the lung. One plausible candidate may 
be an increased activation of lung macrophages. As we explained above, IL-2-
activated mouse NK cells may have induced the polarization of macrophages 
into M1. Aerosol PBS + NK cell therapy also increased survival. However this 
increase in survival was not statistically significant. This was due to variability in 
the therapeutic efficacy seen with aerosol PBS + NK cell therapy. Some mice 
died early in the survival study, while others had an extended life-span. This 
suggests that the addition of aerosol IL-2 to NK cell therapy confers consistency 
in terms of its therapeutic effect.  
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Aerosol IL-2 Toxicity 
 One of the reasons we decided to use aerosol IL-2 to expand NK cells in 
the lung was to avoid the toxicities associated with systemic IL-2. IL-2 can cause 
a myriad of toxicities, including oliguria, hypotension, elevated liver enzymes, 
thrombocytopenia, and capillary-leak syndrome, which can lead to fluid retention, 
adult respiratory distress syndrome and myocardial infarction [49]. Histological 
examination of the lungs, spleen, liver, kidney and heart did not reveal any 
evidence of acute or chronic inflammation, edema, scarring, or other organ 
damage (Figure 21). CBC and serum enzyme levels were all within normal limits 
(Figure 22). There wasn’t any weight associated changes in mice treated with 
aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells (Figure 24). 
Serum IL-2 levels following aerosol IL-2 therapy were well below those found in 
mice treated with intraperitoneal IL-2 (Figure 23). This explains the lack of 
toxicity. This suggests that aerosol therapy concentrates IL-2 in the lung, 
specifically activating the proliferation of the infused human NK cells in the lung 
(Figure 7), with very minimal spill-over into the periphery. This translates into the 
absence of systemic toxicities as well as the absence of IL-2-induced NK growth 
in the liver and spleen (Figure 9), and the minimal activation seen inside the bone 
marrow (Figure 8). Our results are consistent with clinical trials using aerosol IL-
2, which demonstrate minimal toxicities [50, 51] and improved quality of life when 
compared to systemic IL-2 therapy [52]. 

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Limitations of Study 
We used human NK cells for our experiment partly due to the difficulty of 
isolating and expanding mouse NK cells ex vivo.  For this reason, we used 
human osteosarcoma LM7 metastasis in a nude mouse model for our in vivo 
studies. Since nude mice do not have T cells, this had the added benefit of 
limiting any results demonstrating therapeutic effect to the interactions between 
aerosol IL-2, NK cells and the target tumor. However, the model does not present 
a complete picture of what would happen clinically. IL-2 is a potent activator of 
both cytotoxic T cells and regulatory T cells, of which the former may have a 
positive effect on therapy, while the later might limit it. Also, the model does not 
take into account the co-stimulatory relationships between cytotoxic T cells and 
NK cells [16], which could influence the effect of aerosol IL-2 + NK cell therapy. 
The lack of T cells may limit an accurate picture of the toxicity of aerosol IL-2, as 
IL-2 systemic side effects could be attributed to T cell activation. However, we 
addressed this concern by treating BALB/C mice with aerosol IL-2 in our toxicity 
studies (Figure 21) and finding no histological evidence of acute or chronic 
inflammation, scarring or damage in sections of lung, spleen, heart, liver or 
kidney. 
Conclusion 
There is a need for the development of new therapeutics for patients with 
osteosarcoma lung metastasis. In the last 20 years, mifamurtide has been the 
only new therapeutic that has been approved for the treatment of osteosarcoma 
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[10].Our data has shown that the aerosol delivery of IL-2 is an effective way to 
induce selective migration and expansion of NK cells in the lungs. Aerosol IL-2 
also increased human NK cell numbers within lung tumor nodules and increased 
tumor cell apoptosis. This translated into reduced pulmonary metastasis and 
increased survival. Combining aerosol IL-2 therapy with NK cells increased the 
therapetic efficiency of NK cell therapy without causing systemic toxicity. Since 
the safety and tolerability of aerosol IL-2 have already been documented in 
several different clinical trials [50, 51], this organ-specific cytokine delivery 
concept can be exploited to target selective NK cell migration, expansion, and 
activation in the lung.  This combination therapy can therefore serve as a new 
therapeutic approach for patients with relapsed and unresponsive osteosarcoma 
lung metastases. 
FUTURE DIRECTIONS 
Translation into Clinical Trials 
 One of the main purposes of this investigation was to provide pre-clinical 
data testing a novel therapeutic approach for the treatment of osteosarcoma lung 
metastasis with the possible goal of moving forward with a clinical trial. Currently 
a Phase I/II clinical trial is being run in MD Anderson with the purpose of 
determining the highest tolerable dose of aerosol IL-2 and its safety in the context 
of patients with lung metastasis. Among those to be treated with aerosol IL-2 are 
patients with osteosarcoma lung metastasis. Dr. Nancy Gordon (Division of 
Pediatrics, The University of Texas MD Anderson Cancer Center) from Dr. 
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Kleinerman’s laboratory is coordinating this effort. Serum concentrations of IL-2 
will be reported to determine if any peripheral spill-over occurs. Peripheral 
absolute lymphocyte counts will also be recorded. Early lymphocyte recovery 
after chemotherapy has been associated with improved prognosis in pediatric 
patients with osteosarcoma [89]. We would attempt to correlate the effectiveness 
of aerosol IL-2 therapy with absolute lymphocyte counts. Lung tumor biopsies 
would be collected before and after aerosol IL-2 treatment. Using 
immunohistochemistry, we will determine if aerosol IL-2 increases NK cell 
infiltration within the patient lung nodules and we will correlate this data with the 
degree of apoptosis and/or necrosis within the metastatic nodules. If any 
objective response is observed in this clinical trial, we would want to determine if 
it correlates with increased NK cell tumor infiltration and tumor apoptosis. Any 
positive correlation would give impetus to moving forward with a Phase I clinical 
trial examining the use of aerosol IL-2 and NK cell therapy.  
 The purpose of a phase I clinical trial involving the use of aerosol IL-2 + 
NK cells will be to determine the highesttolerable dose and safety of ex vivo 
expanded [39] allogeneic KIR-mismatched NK cells given in combination with 
aerosol IL-2 therapy in the context of patients with osteosarcoma lung 
metastasis. The dose of aerosol IL-2 to be given would be determined by the 
above mentioned clinical trial. To our knowledge, there have been no 
investigations that have reported a peak tolerable dose for infused NK cells. The 
highest dose of NK cells to have been infused into patients has been 4.7 × 1010 ± 
2.1 × 1010 ex vivo expanded autologous NK cells. No toxicities were reported in 
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this study [37]. The most toxic adverse effects associated with NK cell infusions 
have been Grade I and II pruritus, rigors and muscle aches using 2 X 107/kg NK-
enriched KIR mismatched cells [90]. In our investigation we injected 5 X 107 NK 
cells per mouse two times per week for 5 weeks. Considering nu/nu mice weigh 
between 20 and 30 grams, the corresponding NK cell dose should be between 
1.7 X 109 - 2.5 X 109 NK cells/kg for a human patient 2 times per week for 5 
weeks. Since such high numbers of NK cells have never been infused into 
patients before, a gradual increase in NK cell infusions should be attempted in 
order to determine the highest tolerable dose. Patients would be treated with NK 
cell therapy with or without concomitant aerosol IL-2. Therapeutic effect, as well 
as possible NK toxicities, could be exacerbated by the addition of aerosol IL-2. If 
throughout the trial we observe that the addition aerosol IL-2 confers an 
additional therapeutic benefit, we would add aerosol IL-2 to those patients 
receiving NK cell therapy alone. Tumor biopsies would be obtained as well as 
blood samples before and after treatment. We would want to determine the 
degree of NK tumor infiltration as well as tumor apoptosis. We would want to 
determine if increased NK tumor infiltration, increased absolute lymphocyte 
counts and increased peripheral NK cells correlate with increased tumor 
apoptosis and with objective response, if any is seen.  
 After determining the highest tolerable dose and the safety of NK cell 
therapy, a Phase II clinical trial would be designed. If a peak tolerable dose of NK 
cells cannot be established, then the dose to be used in this trial will correspond 
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to the dose associated with the highest objective response and/or with the 
highest degree of tumor apoptosis.  
 As demonstrated by killing assays (Figure 2), NK cell cytotoxicity 
increases with increasing E:T ratio. An E:T of at least 5 is required for maximum 
efficiency. To increase therapeutic efficiency, a Phase II clinical trial should be 
designed so that aerosol IL-2 + NK cell therapy is given in the context of minimal 
residual disease (MRD) or after the surgical excision of the metastatic lesions. 
We would not expect NK cell therapy to successfully destroy a bulky tumor with a 
large surface area. We believe NK cell therapy would be more effective against 
microscopic metastatic foci. Treatment duration would be dependent on the 
Phase I trial that is currently being undertaken to determine the safety of aerosol 
IL-2 therapy and our envisioned Phase I trial that would determine the highest 
tolerable dose of NK cells given in combination with aerosol IL-2. We hope that 
aerosol IL-2 + NK cell therapy will increase the 5-year survival of patients with 
osteosarcoma lung metastasis beyond 33% [5]. 
Soluble NKG2D ligand concentration in patients with osteosarcoma  
 Our data for patient specimens demonstrated that NKG2D ligand 
expression was higher in osteosarcoma lung metastasis than in primary tumors 
(Figure 4). This seems to be counterintuitive in terms of evasion from NK 
immunosurveillance. Decreased expression of NKG2D ligands on colorectal 
cancer correlates with tumor stage progression, with the lowest expression 
associated with stage IV [91]. One of the mechanisms by which tumors with 
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elevated NKG2D ligand expression can evade NK recognition is by shedding 
NKG2D ligands. Indeed, serum soluble MICA is increased in metastasis [92]. In 
melanoma, elevated serum soluble ULBP2 levels correlate with a poorer 
prognosis [93].  
 To asses if osteosarcoma lung metastasis is associated with increased 
NKG2D ligand shedding, we would measure the serum concentration of soluble 
NKG2D ligands in patients with osteosarcoma lung metastasis and compare 
these values to serum concentrations from patients with primary osteosarcoma 
and health patient serum. We would corroborate these data with in vitro studies 
measuring the concentration of soluble NKG2D ligands in the culture media from 
human osteosarcoma cells. We would compare the secretion of NKG2D ligands 
by osteosarcoma cell lines derived from patient pulmonary metastasis and the 
secretion by cell lines derived from primary osteosarcoma. If the results 
demonstrate that osteosarcoma metastasis increases soluble NKG2D ligand 
expression, this could explain how metastatic osteosarcoma cells evade NK 
immunosurveillance even when they have high surface expression of NKG2D 
ligands.  
 Matrix Metalloproteinase 9 (MMP9) is responsible for MICA shedding in 
osteosarcoma. Inhibiting MMP9 prevents MICA shedding and increases 
osteosarcoma susceptibility to NK cytotoxicity [94]. We hypothesize that the 
addition of a MMP9 inhibitor would enhance NK cell therapy against 
osteosarcoma lung metastasis. To test this hypothesis we would first chose a 
human osteosarcoma cell line derived from a patient with pulmonary metastasis 
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capable of secreting high levels of soluble MICA. LM7 would not necessarily 
secrete high levels of  soluble MICA because it was derived from the primary 
human osteosarcoma cell line SAOS-2 after becoming metastatic by passage 
through the lungs of Nu/Nu mice [64]. The ability to secrete soluble human 
NKG2D ligands would not have provided LM7cells with a survival advantage in a 
tumor micro-environment with mouse NK cells because mouse NKG2D does not 
recognize human NKG2D ligands [60]. Once we confirm metastasis, we would 
treat these mice with NK cells that have been expanded ex vivo with IL-2 and 
genetically modified K562 with membrane-bound IL-21 and IL-15 [39] in 
combination with or without a MMP9 inhibitor. We would use mice treated with 
MMP9 inhibitor alone or without treatment as negative controls. Since ex vivo 
expansion growth increases NK cytotoxicity, numbers and life-span, we might not 
discover any increased therapeutic effect by the addition of MMP9 inhibitors. 
Increased cytotoxicity and increased NK life-span may overcome the inhibitory 
effect mediated by soluble NKG2D ligands. To corroborate this, we would repeat 
this experiment with freshly isolated NK cells. Since aerosol IL-2 increases NK 
cell proliferation in the lung, we would also want to determine if combination NK 
cell and aerosol IL-2 treatment can overcome any inhibition provided by soluble 
NKG2D ligands. We would design an experiment similar to the one described 
above with the addition of aerosol IL-2 to the NK cell therapy. If the addition of 
MMP9 inhibitor does not significantly improve the therapeutic efficacy of aerosol 
IL-2 + NK cell therapy, but does improve therapeutic efficacy when added to 
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aerosol PBS + NK cell therapy, we may be able to conclude that co-treatment 
with aerosol IL-2 overcomes the inhibition that is induced by MICA shedding.  
Pharmacological upregulation of NKG2D ligands 
If aerosol IL-2 + NK cell therapy is to be used in clinical trials, we should 
consider the fact that a substantial number of patients with osteosarcoma lung 
metastasis have been exposed to chemotherapeutical agents. Chemotherapy 
may alter the NKG2D ligand expression in osteosarcoma lung metastasis. 
However, since NKG2D ligands are upregulated in response to cellular stress 
[23], chemotherapy may actually aid NK cell therapy.  
Cisplatin, doxorubicin, and high-dose methotrexate with leucovorin are the 
standard chemotherapeutical agents used against osteosarcoma lung metastasis 
[6]. Doxorubicin has been shown to increase NKG2D ligand expression on 
multiple myeloma cells and to enhance their susceptibility to NK cytotoxicity [95].  
To determine if the standard chemotherapy used against osteosarcoma 
increases NKG2D ligand expression, we would obtain patient specimens from 
osteosarcoma lung metastasis before and after chemotherapy and we would 
then do immunohistochemistry staining for NKG2d ligands. We would 
supplement these data with in vitro studies comparing the NKG2D ligand 
expression of osteosarcoma cells before and after treatment with the above 
mentioned chemotherapeutical agents. NK killing assays would also be 
performed to determine if chemotherapeutic treatment of osteosarcoma cells 
enhances NK killing. If our in vitro data and our patient sample data demonstrate 
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that standard chemotherapy against osteosarcoma lung metastasis increases the 
expression of NKG2D ligands, we should consider giving NK cell therapy shortly 
after chemotherapy has been administered to patients.   
We could also investigate alternate chemotherapeutical agents that would 
enhance osteosarcoma NKG2D ligand expression and potentially enhance NK 
cell therapy. For example, our laboratory has successfully demonstrated that 
aerosol gemcitabine treatment of osteosarcoma lung metastasis significantly 
inhibits its growth and increases tumor Fas expression [96-98]. Gemcitabine is 
known to increase the expression of MICA/B in hepatocellular carcinoma and to 
also increase their susceptibility to cytokine-activated killer cells [99]. We would 
design an investigation in order to determine if gemcitabine increases the 
expression of NKG2D ligands in osteosarcoma and if this translates into a 
greater therapeutic efficacy when using NK cell therapy. First, we would 
determine if gemcitabine increase NKG2D ligands in vitro on various 
osteosarcoma cell lines. Next, we would determine if the expression of NKG2D 
ligands in osteosarcoma lung metastasis from mice treated with aerosol 
gemcitabine is increased. We could use a Nu/Nu mice model with human 
osteosarcoma lung metastasis and/or BALB/C mice model with mouse 
osteosarcoma lung metastasis. If we decided to use the BALB/C model, we 
would need to test for the expression of mouse NKG2D ligands. If our results 
demonstrate gemcitabine-induced NKG2D ligand increase, we would perform a 
therapeutic study combining NK cell therapy with aerosol gemcitabine.  
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HDAC inhibitors are promising agents with the potential to increase the 
expression of NKG2D ligands in cancer. Valproic acid increases the expression 
of NKG2D ligands on myeloma [100], ovarian cancer [101], Ewing sarcoma 
[102], hepatoma [103], and AML[104], as well as increasing their susceptibility to 
NK-mediated cytotoxicity. Valproic acid has also been reported to increase the 
expression of MICA/B in osteosarcoma cell, without increasing its soluble form, 
leading to an increased susceptibility to NK killing [105]. In our laboratory, we’ve 
had great success with the use of another HDAC inhibitor, MS-275. Our 
laboratory has shown that MS-275 increases the Fas expression in 
osteosarcoma and induces the regression of osteosarcoma lung metastasis 
[106-108]. Graduate student Simin Kiany is currently investigating the use of MS-
275 to increase the expression of NKG2D ligands in osteosarcoma and using it in 
combination with NK cell therapy to treat osteosarcoma lung metastasis in a 
Nu/Nu mouse model.  
Increasing NK homing toward osteosarcoma metastatic nodules in the lung 
 Aerosol IL-2 increases the number (Figure 5) and proliferation (Figure of 
7) of infused NK cells in the lung, leading to increased NK cell retention in tumor 
nodules (Figure 16), which in turn increases tumor apoptosis (Figure 14) and 
therapeutic efficacy.  Yet, a large proportion of infused NK cells still propagate 
toward the spleen and liver (Figure 6). Finding a way to increase the retention of 
infused NK cells in the lung or to induce their migration from extra-pulmonary 
organs could potentially improve the therapeutic efficacy of NK cell therapy. Our 
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laboratory has started investigating the role chemokines and chemokine 
receptors play in NK cell migration toward tumor locations.  
 The study of the chemokine receptor CX3CR and its ligands shows great 
promise. CXC3CR is a chemokine receptor that is expressed on T cells and 
activated NK cells [109]. Pre-clinical studies report that stimulating the 
expression of CX3CR ligands causes lung cancer regression. Antitumor activity 
was mediated by an increased T cells and NK cell tumor infiltration [110]. The 
clearance of YAC-1 cells in the lung of C57BL/6 is mediated by NK cells and is 
dependent on the interaction between CXC3CR and the chemokine 
CX3CL1[111]. The CXC3CL1/CXC3CR chemokine/receptor axis has also been 
implicated in the eradication of neuroblastoma metastases by T cells and NK 
cells [112]. Gene therapy using aerosolized liposome encapsulated CX3CL1-
encoding plasmids significantly reduced mouse osteosarcoma lung metastasis 
[113].  We can design a pre-clinical trial in which aerosolized gene therapy with 
CX3CL1-encoding plasmids is combined with aerosol IL-2 + NK cells in order to 
maximize the killing of osteosarcoma lung metastasis. Aerosol IL-2 would 
increase the numbers of NK cells in the lung, while CX3CL1 transduction of 
metastatic osteosarcoma cells would enhance the migration of these NK cells 
toward the tumor nodules facilitating tumor cell killing. It could also provide the 
added benefit of attracting the NK cells that would normally propagate toward the 
liver and spleen back toward the tumor sites. For maximum effect, we could 
specifically select and expand NK cells with high expression of CXC3CR. 
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 Another mechanism of exploiting NK chemotaxis toward osteosarcoma 
would be to investigate the normal chemokine expression of metastatic 
osteosarcoma cell lines. We would then determine which of these chemokines 
are more effective in attracting NK cells. We would then selectively isolate and 
expand NK cells with these specific receptors for these chemokines from buffy 
coats for subsequent adoptive ex-vivo expanded NK cell therapy. Dr. Gangxiong 
Huang of Dr. Kleinerman’s laboratory is currently working on this project. 
Recently Somanchi et al [114] engineered a way to successfully transfer the 
chemokine receptor CCR7 to ex vivo expanded NK cells by incubation with 
CCR7-expressing K562s. The plasma membranes of these NK cells acquired 
CCR7 via trogocytosis. These NK cells could express CCR7 for 72 hours. This 
transient expression of CCR7 successfully enhanced the migration of NK cells 
toward the lymph nodes of athymic nude mice. We could select specific 
chemokines that are actively expressed in osteosarcoma cells of metastatic 
origin. We would design a pre-clinical study in which ex vivo expanded NK cells 
are incubated with K562s expressing the chemokine receptor or receptors for 
these chemokines. This could potentially enhance the migration of NK cells 
toward osteosarcoma metastatic cells in the lung and enhance therapeutic effect.   
Exploiting the cross-talk between Macrophages and NK cells 
 Preliminary unpublished data from our laboratory demonstrates increased 
macrophage infiltration of lung osteosarcoma metastasis in Nu/Nu mice treated 
with aerosol IL-2. Nu/Nu lack T cells and mouse NKG2D does not recognize 
human NKG2D ligands [60]. Increased macrophage infiltration could explain the 
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reason we see a therapeutic effect in Nu/Nu mice with human osteosarcoma 
metastasis that have been treated with aerosol IL-2 alone. Aerosol IL-2 may 
activate mouse NK cells in the lung, and this activated NK cells might 
subsequently activate lung macrophages. NK cells are known to secrete a variety 
of cytokines that can activate monocytes/macrophages, including INFܵ, TNFĮ, 
MIP-1Įȕ, and GM-CSF. Macrophages in turn secrete IL-12 and IL-18 to activate 
NK cells [16]. Physical contact between macrophages and NK cells increases the 
expression of NKG2D [115]. Activated NK cells have the ability to shift 
macrophage polarization toward M1. They do this by killing M0 and M2 
macrophages, but sparring M1 macrophages [86]. This suggests an important 
role for macrophages in NK-mediated tumor regression.  
 We could test this hypothesis by first determining the state of polarization 
in the macrophage infiltrate of aerosol PBS-treated, aerosol IL-2-treated, aerosol 
PBS + NK cell-treated and aerosol IL-2 + NK cell-treated LM7 osteosarcoma lung 
metastasis in Nu/Nu mice. Markers for M1 polarization are CD68/HLA-DR, and 
those for M2 are CD68/CD163 [116]. If NK-mediated activation of macrophages 
to a M1 polarized state is associated with NK-mediated tumor regression, we 
would see an increased M1 polarized state in the lung metastasis that have been 
treated with aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 + NK cells 
when compared with aerosol PBS treatment. NK cell-macrophage crosstalk is 
dependent on both cytokine secretion and physical contact. Human NK cells 
might still activate mouse macrophages by the secretion of certain cytokines, but 
the activation induced by cell-to-cell contact may be lost. For example, one of the 
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ways human macrophages activate human NK cells is by the expression of MICA 
[117]. This would not be possible between human NK cells and mouse 
macrophages, as mouse macrophages would lack human NKG2D ligands. For 
this reason, we may not see much difference in terms of M1 polarization when 
we compare aerosol IL-2, aerosol PBS + NK cell and aerosol IL-2 + NK cell-
treated tumors.  
  If macrophage activation is important for NK-mediated tumor regression, 
we could potentially enhance this regression by the addition of macrophage 
activators. As mentioned before, L-MTP-PE has been the only new therapeutic 
that has improved survival in osteosarcoma patients [10]. Since L-MTP-PE is a 
direct macrophage activator and since NK cells and macrophages can co-
stimulate each other, a combination therapy with aerosol IL-2 + L-MTP-PE + NK 
cells could be a novel and effective therapeutic regiment against osteosarcoma 
lung metastasis.  
Aerosol therapy with other NK activating cytokines 
In this investigation we used aerosol IL-2 for the stimulation of NK cells in 
the lung due to IL-2’s well known effect on NK cells. However, there are a variety 
of other cytokines that are known to stimulate NK cells. IL-15 is another well-
known activator of NK cells and it shares structural similarities with IL-2 [118]. 
Similar to IL-2, it promotes the survival, proliferation and cytotoxic activity of NK 
cells. IL-12 is another cytokine known to activate NK cells, specifically by 
stimulating its production of INF- ܵ [119]. Moreover, it has anti-antiangiogenic 
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effects specifically modulated through NK cells [120]. However, its capacity to 
induce NK proliferation is lower than that of IL-2 or IL-15 [121]. IL-21 can 
increase NK cells cytokine productions and cytotoxicity, but in some cases has 
been shown to limit their proliferation [17]. IL-15 and IL-21 have the added 
benefits of being able to downregulate regulatory T cell numbers [122, 123].  
 To our knowledge, aerosolized forms of these cytokines have not been 
developed. Our lab studied the aerosol gene therapy with PEI: IL-12 in order to 
eradicate osteosarcoma lung metastasis, but the aerosol delivery of the actual 
cytokine was not evaluated [124]. In theory, if aerosolized forms of these 
cytokines were to be developed, we could study their effect on NK recruitment to 
the lung and its tumoricidal properties. In vivo experiments would be designed to 
compare their capacities to increase injected NK cells in the lung, to increase NK 
infiltration of osteosarcoma lung metastasis and their overall ability to enhance 
NK cell therapy. In addition, different combinations of these aerosolized would be 
evaluated, as studies have shown that they have synergistic effects on NK 
activation [118, 125]. The combination of IL-2 and IL-21 is of particular interest, 
as IL-21 addition to IL-2 has the capacity to counteract IL-2’s driven regulatory T 
cell expansion [123].  
Exploring the possible effect of aerosol IL-2 on the stimulation of 
regulatory T cells 
The inadvertent stimulation of regulatory T cells is of concern for any 
therapy involving the use of interleukin-2. Patients receiving IL-2 therapy have 
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elevated levels of peripheral regulatory T cells [126]. Regulatory T cells can 
specifically inhibit NK cell activity [83, 127]. Low dose IL-2 therapy increases the 
proliferation of regulatory T cells in patients with chronic graft-versus-host 
disease, with no effect on other CD4+ T cells [128]. This may prove a concern 
since our data shows that treatment with aerosol IL-2 for 5 weeks increases 
serum IL-2 levels, but to very low levels (Figure 23). Whether or not these levels 
would correspond to those that selectively increase regulatory T cells would have 
to be determined. Since we used nude mice for our treatment experiments, any 
negative effect on therapy that might have been caused by an IL-2 induced 
increase in regulatory T cells would not have been apparent.  
 In order to determine if aerosol IL-2 therapy can increase regulatory T cell 
populations, an animal experiment in which immunocompetent mice are given 
aerosol IL-2 for at least five weeks would be designed. Treatment for 5 weeks is 
essential, since at that time we saw increased serum IL-2 levels. The peripheral 
and lung population of regulatory T cells would be monitored from the day before 
treatment is started, during the treatment window and afterward. IL-2 serum 
levels would also be measured through the study. We would compare the 
regulatory T cell population of these mice before the start of treatment and right 
after the start of treatment. If there is an increase, we would want to correlate 
these numbers with the corresponding values of serum IL-2. We would keep 
monitoring regulatory T cell levels after treatment has ended until serum IL-2 
levels have returned to normal. We would also want to monitor CD4+T cell levels 
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throughout the study, as any increase in regulatory T cell levels might just be 
proportional to increases in helper T cell levels.  
 If we do find an increase in regulatory T cell levels caused by low level 
increases of serum IL-2, we would determine if these correlate with decreased 
effectiveness of treatment. We would not be able to treat immunocopentnet mice 
with ex vivo expanded human NK cells, so the treatment would have to be limited 
to aerosol IL-2. We would design a lung metastasis model using BALB/C mice 
engrafted with mouse metastatic osteosarcoma cell line K7M3. We would treat 
these mice with aerosol PBS or aerosol IL-2 for 5 weeks. We would sacrifice 
these mice and extract their lungs at different time points during treatment. We 
would measure serum IL-2 levels and regulatory T cell populations at the 
moment of euthanasia. Lung tumors would be stained for TUNEL, mouse NK cell 
markers and regulatory T cell markers. We would then determine if NK tumor 
infiltration and tumor apoptosis decreases with increasing serum IL-2 levels and 
regulatory T cell numbers.  
 
Exploring the effect of high dose and low dose IL-2 in the stimulation of NK 
cells and its relationship to regulatory T cells 
As mentioned above, low-dose IL-2 therapy increases peripheral regulatory T 
cells [126] . As figure 23 demonstrates, aerosol IL-2 treatment for 5 weeks can 
cause a very low up regulation of serum IL-2. In the setting of immunocompetent 
organisms, an upregulation of regulatory T cells could potentially interfere with 
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NK cell therapy. To address this concern, we could potentially study the effect of 
high and low doses of IL-2 on NK cell cytotoxicity and proliferation, on regulatory 
t cells as well as the interactions between the two.  
 First, we would treat freshly isolated human NK in vitro with IL-2 doses 
that would correspond to low-dose IL-2 therapy that induces expansion of 
peripheral regulatory T cells in vivo. We would measure rate of proliferation, the 
expression of activating receptors such as NKG2D, and their in vitro cytotoxicity 
against osteosarcoma cell lines. These values would be compared to those from 
unstimulated NK cells and from NK cells treated with our standard dose of IL-2. 
Second, we would treated freshly isolated regulatory T cells with the same doses 
and compare their rate of proliferation and their expression of defining T cell 
markers. We would be particularly interested in determining if low-dose IL-2 
stimulates regulatory T cell proliferation at higher levels than high-dose IL-2 
treatment. Subsequently, we would determine the effect of low-dose stimulated 
regulatory T cell as well high-dose stimulated regulatory T cells on NK 
cytotoxicity by co-culturing them with NK cells that had been untreated or treated 
with low-dose or high-dose IL-2.  
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Osteosarcoma cell lines and culture 
 Human osteosarcoma cell lines KRIB, LM7, CCH-OS-D, U2OS, and TE-
85 and mouse K7M3 cells were cultured in complete Dulbecco’s Modified Eagle’s 
Medium (Whittaker Bioproducts Inc., Walkersville, MD) supplemented with 2 
mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 1 mmol/L nonessential amino 
acids, 2 mmol/L minimal essential medium vitamin solution and 10% heat-
inactivated bovine serum (Intergen, Purchase, NJ). LM7 is a human 
osteosarcoma lung metastatic cell line that was created in our laboratory by 
repeated intravenous recycling of its parent cell line SAOS-2, through nude mice 
lungs [64]. CCH-OS-D cells were kindly provided to us by Dennis Hughes, MD, 
PhD (Division of Pediatrics, The University of Texas MD Anderson Cancer 
Center). K7M3 mouse osteosarcoma cell line was created in our laboratory by 
injecting K7M2 intravenously into BALB/C mice and harvesting the lung 
metastasis [97]. All cell lines were mycoplasma-negative and validated by short 
tandem repeat DNA Fingerprinting using the AmpFLSTR Identifier kit (Applied 
Biosystems, Carlsbad, CA). The authenticity of cells was determined by the 
Characterized Cell Line Core at The University of Texas MD Anderson Cancer 
Center. 
Human NK cells: Isolation, ex vivo expansion and culture 
Blood samples were obtained from healthy adult volunteer donors (Gulf 
Coast Regional Blood Center, Houston, TX) following informed consent. Human 
NK cells were harvested from buffy coat fractions using the RosetteSep Human 
NK Cell Enrichment Cocktail (Stem Cell Technologies, Vancouver, BC) and 
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Ficoll-Paque PLUS (GE Healthcare Life Sciences,Little Chalfont, UK) [39]. NK 
cells were cultured in RPMI medium (Cellgro/Mediatech, Manassas, VA) 
supplemented with 10% heat-inactivated bovine serum (Intergen), 2 mmol/L 
glutamine, 1 mmol/L sodium pyruvate and 50 IU/ml recombinant human IL-2 
(Proleukin, Novartis, Inc., Basel, Switzerland). Genetically-engineered K562 cells 
with membrane-bound IL-15 and membrane-bound IL-21 were used as artificial 
antigen presenting cells [aAPC] after 100-Gy g-irradiation for in vitro expansion of 
isolated human NK Cells [39]. Every 3 days cultures were refreshed with media 
changes. Every 7 days the cultures were re-stimulated with K562s at 1:2 PBMC 
to aAPC ratio. When further NK cell purity or T cell depletion was required, third 
party red blood cells were added to enhance agglutination and to remove 
unwanted cells [129].  
 
Flow Cytometry 
The phenotypes of expanded NK cells were analyzed weekly using flow 
cytometry. Phycoerythrin [PE]-conjugated mouse anti-human NKG2D, PE-
conjugated mouse anti-human CD16, PE-conjugated mouse anti-human CD3, 
and Allophycocyanin [APC]-conjugated mouse anti-human CD56 (BD 
Pharmingen, San Diego, CA) were used to monitor NK cell phenotype. For direct 
surface staining, NK cells were suspended in FACS buffer (PBS, containing 2% 
fetal calf serum and 0.1% sodium azide) and incubated with the indicated 
antibodies for 20 minutes at 4°C. Data was acquired using a FACSCalibur 
cytometer (BD Biosciences, San Jose, CA) and analyzed using the FlowJo 
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software (Tree Star, Inc., Ashland, OR). APC and PE-conjugated isotype-control 
IgG antibodies were used as negative controls (BD Pharmingen). Human NK 
Cells were defined as CD56+, CD16+, NKG2D+ and CD3-. A purity of at least 95% 
was deemed appropriate for further use. 
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human HLA-
ABC (BD Pharmingen), PE-conjugated mouse anti-human MIC A/B (BD 
Pharmingen), PE-conjugated mouse anti-human ULBP2/5/6 (R&D Systems, 
Minneapolis, MN), PE-conjugated mouse anti-human ULBP3 (R&D Systems), 
and (PE)-conjugated mouse anti-human ULBP1 (R&D Systems) were used to 
determine HLA and NKG2D ligand expression on human osteosarcoma cells. For 
direct surface staining, osteosarcoma cells were suspended in FACS buffer 
(PBS, containing 2% fetal calf serum and 0.1% sodium azide) and incubated with 
the indicated antibodies for 20 minutes at 4°C. Data was acquired using a 
FACSCalibur cytometer (BD Biosciences) and analyzed using the FlowJo 
software (Tree Star, Inc.). APC, FITC and PE-conjugated isotype-control IgG 
antibodies were used as negative controls (BD Pharmingen). 
To determine the percentage of proliferating human NK cells, single-cell 
suspensions derived from nu/nu mice lungs, liver, spleen and bone marrow were 
stained with PE-conjugated mouse anti-human NKp46 (BD Pharmingen) and 
FITC-conjugated mouse anit-BrdU (eBiosciences, San Diego, CA). For cell 
surface staining, cells were suspended in FACS buffer (PBS, containing 2% fetal 
calf serum and 0.1% sodium azide) and incubated with the anti-NKp46 antibody 
for 20 minutes at 4°C. Cells were then permeabilized in 70% ethanol for 30 
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minutes on ice, followed by Brdu intracellular staining in FACS buffer (PBS, 
containing 2% fetal calf serum and 0.1% sodium azide) with anti-Brdu incubation 
for 20 minutes at 4°C. Data was acquired and analyzed as described above.  
Cytotoxicity Assays 
NK mediated-cytotoxicity against osteosarcoma cells following a four hour 
co-incubation period was measured using a [3H]thymidine incorporation assay 
[130]. Radioactive incorporation was quantified using the Beckman Coulter® LS 
6500 Multipurpose Scintillation Counter (Brea, California). The percentage of 
cytotoxicity was calculated by the following formula: % of cytotoxicity = [(AíB)/A] 
× 100. A is the radioactivity in counts per minute [cpm] of osteosarcoma cells 
treated with medium alone, and B is the radioactivity cpm osteosarcoma cells 
treated with human NK cells.  
 To determine the importance of NKG2D-ligand interaction, cytotoxicity 
assays were performed where NKG2D or a NKG2D ligand was blocked. 
Osteosarcoma cells were plated in triplicate on 96-well plates labeled with 0.2 
ȝCi/well of [3H] thymidine for 24 hours at 37°C, washed twice with PBS and then 
incubated with 0 µg/mL, 5 µg/mL, or 10 µg/mL mouse anti-human ULBP2/5/6 
(R&D Systems) for 24 hours at 37°C. The cells were then washed twice with PBS 
and co-cultured with increasing concentrations of human NK cells for 4 hours at 
37°C, incubated with 0µg/ml, 5µg/ml, or 10µg/ml mouse anti-human NKG2D 
(R&D Systems). Prior to co-culture with osteosarcoma cells, NK cells were 
incubated with mouse anti-human NKG2D (R&D Systems) for 1 hour at 37°C. 
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[3H] thymidine radioactive incorporation and cytotoxicity were quantified as 
described above. 
Patient Osteosarcoma Samples 
Microarray slides from paraffin-embedded osteosarcoma tumor specimens 
contained 47 primary osteosarcoma samples and 56 osteosarcoma pulmonary 
metastasis samples. The institutional review board approved medical record 
reviews for the current study. (Originally published in Pediatric Blood and Cancer 
2013. This material is reproduced with permission of John Wiley & Sons, Inc.) 
To evaluate immunohistochemical evidence for NKG2D ligand expression, 
these microarray tissue sections were deparaffinized in xylene and rehydrated. 
Incubation at 95°C in citrate buffer for 20 minutes was conducted for antigen 
retrieval. Incubation with 3% H2O2 for 12 minutes was performed to block against 
endogenous peroxidase followed by protein block with 4% fish gelatin in PBS. 
Sections were incubated with 50µg/ml recombinant human NKG2D/Fc Chimera 
(R&D Systems) overnight at 4°C. Horseradish peroxidase goat anti-human 
secondary antibody (Jackson ImmunoResearch, Inc., West Grove, PA) was then 
applied for one hour at room temperature [RT] at 1:500 dilution in protein block, 
followed by 3,3#-diaminobenzidine [DAB] 10 minute incubation and light 
counterstain with hematoxylin. Sections not exposed to recombinant human 
NKG2D/Fc Chimera served as negative controls. The expression of the NKG2D 
ligand ULBP2 is high in terminally differentiated cells in normal human cervix 
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epithelium [131]. Thus, sections of normal human cervix epithelium (US Biomax 
Inc., Rockville, MD) were used as positive control.  
Animal studies 
All animal experiments were approved by the Institutional Animal Care 
and Use Committee at MD Anderson Cancer Center. Female four-week old 
athymic nu/nu mice and BALB/C mice were purchased from the Natural Cancer 
Institute (Bethesda, MD). All mice were housed in standard cages, at five mice 
per cage.  
 Aerosol treatment was performed as described previously [132]. PBS 
suspension (10 ml) with or without recombinant human IL-2  [IL-2] (TECINTM 
Teceleukin, Bulk Ro 23-6019, National Cancer Institute, Frederick, MD) was 
added to an AeroTech II nebulizer (CIS-USA, Bedford, MA). The nebulizer was 
operated at a flow rate of 10 liters of air per minute. Mice were placed 
unrestrained in a sealed plastic cage and exposed to the aerosol for one hour. 
The aerosol particles were generated with 5% CO2-enriched air obtained by 
mixing normal air and CO2 with a blender (Bird3M, Palm Springs, CA). The CO2 
concentrations were calibrated with a Fluid Fyrite (Bacharach, Inc., Pittsburgh, 
PA).  
To determine human donor NK cell retention in mouse lungs without 
metastasis, 2 groups of nu/nu mice were treated with aerosol IL-2 @ 2000 U or 
aerosolized PBS. We injected 50 million CM-DiITM (Molecular Probes, Eugene, 
OR)-labeled human NK cells/mouse intravenously through the tail vein. Aerosol 
treatment was administered 24 hours prior to NK cell injection, the day of NK cell 
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injection, and then every other day for 1 week. Mice were killed 1 day, 3 days or 
1 week after NK injection. The lungs, spleen, liver, heart and kidneys of the mice 
were removed, embedded in Tissue-Tek optimum cutting temperature compound 
[OCT] (Fischer Scientific, Hampton, NH), and frozen. Lungs were expanded with 
OCT: PBS at a 1:1 dilution before freezing. (Originally published in Pediatric 
Blood and Cancer 2013. This material is reproduced with permission of John 
Wiley & Sons, Inc.) 
 In order to compare the proliferation of human donor NK cells in mice, 2 
groups of nu/nu mice were injected with 50 million human NK cells and treated 
with either aerosol IL-2 @ 2000 U or aerosolized PBS as described above. Mice 
were killed 24 and 72 hours after NK cell intravenous injection. They were 
injected intraperitoneallywith BrdU (Invitrogen, Carlsbad, CA) 3 hours prior to 
euthanasia. The lungs, spleens and livers were harvested and minced. Single-
cell suspensions were prepared by passage through cell strainers (BD 
Biosciences). Bone marrow cells were obtained by flushing femurs and iliac crest 
with ice cold PBS. Red blood cells were lysed by incubating single cell 
suspensions in Ammonium Chloride Solution (StemCell Technologies, 
Vancouver, BC).  
In order to assess acute and chronic toxicity of aerosol IL-2, 
immunocompetent BALB/C mice were treated with either aerosol IL-2 @ 2000 U 
or aerosol PBS every other day for 1 week. Mice were killed 3 days and 1 week 
after the start of treatment and 1 month after the treatment ended. The lungs, 
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spleen, liver, heart and kidney of the mice were removed, fixed in formalin, and 
embedded in paraffin. 
To determine the therapeutic effect of aerosol IL-2 + human NK cells on 
lung metastasis, 3 million LM7 cells/mouse were injected intravenously through 
the tail vein of nu/nu mice. The presence of micrometastasis was confirmed at 5 
weeks in a group of 3 mice. Treatment was then initiated with aerosol PBS, 
aerosol IL-2, aerosol PBS + human NK cells or aerosol IL-2 + human NK cells 6 
weeks after LM7 injection. Aerosol therapy continued every other day for 5 
weeks. NK cell injections (5 x 107 cells/mouse) were given 2 times a week 
starting 1 day after the first aerosol treatment. Mice were sacrificed 5 weeks after 
start of treatment. Lungs were extracted, expanded with OCT:PBS at a 1:1 
dilution, embedded in OCT and frozen. Spleen, liver, heart and kidneys were 
removed, fixed in formalin and embedded in paraffin. (Originally published in 
Pediatric Blood and Cancer 2013. This material is reproduced with permission of 
John Wiley & Sons, Inc.). Ten animals were used per group. This experiment 
was repeated twice to verify results. Data shown is representative of one 
experiment.  
To assess aerosol IL-2 toxicity, complete blood count [CBC] and liver 
enzyme blood chemistry were analyzed in nu/nu mice that were treated with 
aerosol PBS or aerosol IL-2. Serum IL-2 concentrations were determined using a 
Human IL-2 High Sensitivity ELISA kit (eBioscience), with absorbance measured 
using a SpectraMax Plus384 Absorbance Microplate Reader (Molecular Devices, 
Sunnyvale, CA). (Originally published in Pediatric Blood and Cancer 2013. This 
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material is reproduced with permission of John Wiley & Sons, Inc.) Three mice 
were used per treatment group. 
Survival studies were performed using 10 nu/nu mice per group using the 
same method as described above to establish lung metastasis. The presence of 
micrometastasis was confirmed at 5 weeks in a group of 3 mice. Treatment was 
then initiated as described above and continued for 5 weeks. Aerosol PBS, 
aerosol IL-2, aerosol PBS + NK cell and aerosol IL-2 + NK cell treated mice were 
observed to determine their survival rates. 
 
Immunofluorescence 
To determine the presence of CM-DiI-labeled human NK cells in mouse 
organs following therapy,  frozen sections of lung, spleen, liver, kidney and heart 
were fixed in acetone and stained with Hoechst33342 nucleic acid stain 
(Molecular Probes) at a 1:10,000 dilution in PBS. The corresponding organs of 
mice not treated with CM-DiI-labeled human NK Cells were used as the controls. 
(Originally published in Pediatric Blood and Cancer 2013) This material is 
reproduced with permission of John Wiley & Sons, Inc.) 
Frozen sections of lung with LM7 osteosarcoma metastasis were also 
examined for the presence of NK cells using anti-human NKG2D antibody.  
These frozen sections were incubated with 5% horse serum and 1% goat serum 
in PBS for 30 minutes and then incubated overnight 4°C with AffiniPure Fab 
Fragment goat anti-mouse IgG (Jackson ImmunoResearch, Inc.). Sections were 
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then incubated overnight at 4°C with mouse anti-human NKG2D (eBioscience), 
followed by incubation with goat anti-mouse Alexa Fluor® 546 (Molecular 
Probes) at RT for 1 hour and then with Hoechst33342 blue (Molecular Probes) 
for ten minutes. Negative controls were made by omission of the primary 
antibody. Mean fluorescence per field was quantified in 5 random fields for each 
section by using the Simple PCI software (Hamamatsu, Inc., Bridgewater, NJ). 
Mouse NK cells present in LM7 osteosarcoma metastasis were visualized by 
immunofluorescence using (PE)-conjugated rat anti-mouse NKp46 (BD 
Pharminogen) as described above.  
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) staining.  
 
Frozen tumor sections were fixed with 4% paraformaldehyde and 
incubated with Proteinase K (Promega DeadEnd  Fluorometric TUNEL System, 
Fitchburg, WI) for 10 minutes, incubated with  3% H2O2 for 12 minutes to block 
endogenous peroxidase, and then incubated over night at 4°C with recombinant 
terminal transferase (Promega DeadEnd Flourometric TUNEL System) and 
biotin-16-dUTP (Roche Applied Sciences, Indianapolis, IN). Sections were then 
treated with 2% bovine serum albumin plus 5% normal horse serum in distilled 
water for 10 minutes, followed by 30-minute incubation with 4+Streptavidin-HRP-
Label (Biocare Medical, Concord, CA). This was followed by a DAB 10 minute 
incubation and light counterstain with hematoxylin. Mean positive TUNEL 
staining was quantified by the Simple PCI software (Hamamatsu, Inc.) in 5 
random fields for each section.  
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Statistical analysis 
The unpaired Student’s t-test was used to evaluate the significance of 
differences between experimental groups with a Gaussian distribution of values. 
The Mann-Whitney U rank sum was used to evaluate the significance of 
differences between experimental groups with non-Gaussian distribution of 
values. The inverse correlation between apoptosis and tumor number was 
evaluated using Spearman’s rank correlation test and a linear regression 
analysis. P<0.05 was considered significant. Survival studies were analyzed 
using the log-rank test. 
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Presence of regulatory T cells in the NK cell population 
 
 One concern behind any use of IL-2 treatment is the inadvertent activation 
of regulatory T cells [126], which can limit the immune anti-tumor response. 
Regulatory T cells are known to suppress the immune response [133, 134], as 
well as specifically inhibit NK cell activity [83, 135]. Regulatory T cells are defined 
as CD4+CD25+Fxop3+  T cells [136]. Work performed by current lab member Ling 
Yu, MD (Division of Pediatrics, The University of Texas MD Anderson Cancer 
Center) demonstrated that aerosol IL-2 @ 2000 U treatment, given every other 
day for 15 days to immunocompetent BALB/C mice would increase both CD4+ 
and CD8+ T cells in the lung parenchyma. The number of CD4+Foxp3+ T cells 
was also increased, but their increase was proportional to the overall increase in 
the number of CD4+T cells (unpublished data). Since aerosol IL-2 did not 
increase the percentage of CD4+Foxp3+ T cells among CD4+ T cells, we do not 
expect the presence of regulatory T cells to hinder the aerosol IL-2 treatment.   
 Since we used interleukin-2 to expand human NK cells, we wanted to rule 
out any contamination with and subsequent expansion of regulatory T cells in our 
ex-vivo expanded NK population. We stained for the presence of regulatory T 
cells in our NK population at different time-points during expansion. Regulatory T 
cells can be identified as CD4+CD25+CD127(low/-)[137]. We stained the NK 
population with Phycoerythrin [PE]-conjugated mouse anti-human CD25 (BD 
Biosciences), Allophycocyanin [APC]-conjugated mouse anti-human CD4 (BD 
Pharmingen ) and Fluorescein isothiocyanate (FITC)-conjugated mouse anti-
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human Cd127(BD Pharminogen). Data was acquired using a FACSCalibur 
cytometer (BD Biosciences) and analyzed using the FlowJo software (Tree Star, 
Inc.). The percentage of regulatory T cells among our expanded NK population 
was minimal (Figure A1). Freshly isolated PBMCs from buffy coats contain 0.1 % 
± 0.018 regulatory T cells. Expansion for one week significantly increases this 
percentage to 1.4% ± 0.15 (P = 0.01). This percentage declines to 0.98% ± 0.32 
at 2 weeks of expansion and subsequently declines to 0.17% ± 0.12after 3 
weeks of expansion. There was a significant decline in the percentage of 
regulatory T cells when we compare the population from week 1 and week 2 to 
the population from week 3 (P = 0.007, P = 0.045; respectively). This 
demonstrates that, although IL-2 treatment increases the ex vivo regulatory T cell 
population initially, the effect is not sufficient to go in par with NK cell expansion. 
We believe this low percentage of regulatory T cells will not significantly impair 
NK cell function. All of our NK cell studies were performed with human NK cells 
that had been expanded for 3 weeks.  
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Figure A1: Regulatory T cell population during human NK cell ex vivo expansion.  Ex 
vivo human NK cell populations were monitored for the presence of regulatory T cells. P<0.5 
was considered significant 
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